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RESUMEN 
 
El melanoma cutáneo es un tipo de cáncer con origen en los melanocitos que se vuelven 
malignos. El tratamiento del melanoma cutáneo ha evolucionado mucho en los últimos 
treinta años, sin embargo, no ha conseguido incrementar significativamente la 
supervivencia de los pacientes con cáncer avanzado. Además, el tratamiento presenta 
muchas limitaciones, como una reducida especificidad, efectos secundarios graves y 
multi-resistencia a los fármacos.  
 
De hecho, un paso importante para el éxito del tratamiento del melanoma es su 
detección precoz. En el caso de que no haya metástasis, el cáncer puede ser extirpado 
por cirugía, pero hay casos en que el riesgo de la intervención, así como el elevado 
riesgo de recurrencia, obligan a un tratamiento adyuvante. Actualmente, sólo está 
aprobado un tratamiento adyuvante, con interferón alfa, para estos casos.   
 
De este modo, el principal objetivo de esta tesis es el estudio de alternativas para 
tratamientos adyuvantes, más eficientes y menos agresivos, del melanoma cutáneo. En 
este contexto, se han estudiado dos estrategias para aplicación de sistemas de 
nanopartículas. La primera estrategia consiste en el desarrollo de nanopartículas de oro, 
cubiertas con polímeros naturales y péptidos, con absorción en la región del infrarojo 
próximo, para terapia fototérmica. La segunda estrategia incluye el desarrollo de 
nanopartículas hibridas, para encapsulación de compuestos antitumorales, cubiertas 
con polímeros naturales y péptidos, capaces de una acción química local en el tumor. 
Conjuntamente, hemos investigado el comportamiento físico-químico y la estabilidad de 
las nanopartículas para cada aplicación. Reconociendo la importancia de un tratamiento 
eficaz y específico, ambas las estrategias se basan en un direccionamiento específico 
hacia las células de melanoma, que sobre-expresan múltiples receptores en su 
superficie. Por fin, se utilizaron modelos animales de melanoma humano para 
evaluación de la eficacia de las dos formulaciones propuestas.  
 
En conclusión, es posible desarrollar nanosistemas que comprenden diferentes 
estrategias terapéuticas, basadas en núcleos con estructuras distintas y 
funcionalización de superficies con múltiples ligandos, para una aplicación amplia y 
exitosa en los cánceres heterogéneos, tales como el melanoma cutáneo. 
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ABSTRACT  
 
Cutaneous melanoma occurs on the skin and is the most common type of melanoma. 
Treatment of cutaneous melanoma has improved over the last thirty years; however, 
without demonstrating a significant increase on survival of patients with advanced 
disease. Indeed, conventional treatment generally shows several limitations, such as 
reduced target specificity, severe adverse effects and multiple drug resistance. 
 
In fact, an important step for the success of melanoma treatment is its early detection. In 
cases where there are no metastases, this cancer can be removed by surgery, but in 
some cases the risk of intervention has to be measured, as well as the high risk of 
recurrence, which impose the use of an adjuvant treatment. Currently, there is only one 
adjuvant treatment approved, with interferon alpha, in these cases.  
 
Therefore, the main objective of this thesis was the study of alternatives as adjuvant 
treatments, more efficient and less aggressive, for cutaneous melanoma. In this context, 
two strategies have been studied for application of nanoparticles systems. The first 
strategy is focused on the development of gold nanoparticles, coated with natural 
polymers and peptides, with absorption at the near infrared range, for photothermal 
therapy. The second strategy includes the development of hybrid nanoparticles, for 
encapsulation of anti-tumor compounds, coated with natural polymers and peptides, 
capable of a local chemotherapy at the tumor site. Overall, the physico-chemical 
behavior and stability of both nanoparticles for each application were investigated. 
Recognizing the importance of an efficient and specific treatment, both strategies were 
based on a specific targeting to melanoma cells, which overexpressed multiple receptors 
at their surface. At last, animal models for human melanoma were used for evaluation of 
the efficiency of both proposed strategies.  
 
In conclusion, it is possible to develop nanosystems comprising different therapeutic 
strategies, based on distinct core structures and surface functionalization with multiple 
targeting ligands, for a broad and potential application in heterogeneous cancers, such 
as cutaneous melanoma. 
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INTRODUCTION  
 
Biocompatible and biodegradable materials, explored since the mid- 1960’s for drug 
delivery systems [1], were refined over the years to improve drug absorption and 
bioavailability. The main challenge in this field is still to increase targeted cellular uptake 
without reducing cell viability and permanent membranes’ disruption of surrounding 
tissues. Drug delivery systems based on biomaterials – natural, synthetically or semi-
synthetically produced – are gradually increasing. In general, biomaterials include both 
biomacromolecules (e.g., lipids, proteins and polysaccharides) and inorganic materials 
(e.g., gold, silica and magnetite). Generally Recognized as Safe (GRAS) materials, 
biomacromolecules are used as polymers that combine safety and biodegradability with 
ideal characteristics to promote drug stability and target delivery [2]. They are also 
cheaper to produce than synthetic polymers and can be modified, physically or 
chemically, to obtain the desirable characteristics, such as: controlled drug release, 
stimuli-responsive activation (e.g., pH, temperature and ionic strength) and “stealth” for 
opsonization or enzymes, by penetrating naturally into cells [3]. Biomacromolecules also 
increase drugs’ molecular weight and target absorption to prolong their half-life 
circulation [4].  
 
Beside biocompatibility and biodegradability improvement, these biomacromolecules 
can form stable and efficient drug carriers via electrostatic or hydrophobic interactions, 
innovating the actual pharmaceutical procedures into cleaner and organic solvent-free 
ones. Proteins, peptides, polysaccharides and lipids can be used as isolated polymers 
for formulation of drug delivery systems. Moreover, unlimited possible conjugations 
between these molecules open other possibilities and outcomes to pharmaceutical 
formulations, through the creation of “smart materials”. Therefore, innovative nano-sized 
technologies can push more drugs (e.g., poor-soluble molecules) further in research 
pipelines and, eventually, be used in clinical medicine. Mimicking the natural processes 
that happen in the human body may be one way to create safer and more biocompatible 
drug carriers, improving our health and the efficacy of our medicines.  
 
Hybrid nanoparticles for cancer treatment 
 
Polyester-based nanoparticles 
Polyester-based particles are commonly formed as the core structure of polymeric-
coated nanosystems, by simple adsorption or chemical reactions, with other molecules 
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that promote a sustained or prolonged drug release, compared to uncoated systems [5]. 
These polyester-based particles are made of hydrophobic polymers, such as poly(lactic  
acid) (PLA), poly(lactide-co-glycolide) (PLGA) and  poly(Ɛ-caprolactone) (PCL), and act 
as a stable drug reservoir [6,7]. In cancer therapy, polyester-based nanoparticles are 
used for encapsulating chemotherapy agents, typically water-insoluble compounds, 
increasing their bioavailability, stability and anti-tumor effect [8]. Polyesters are 
biocompatible and biodegradable materials, which undergo in vivo enzyme-catalyzed 
hydrolysis, and nanoparticles are generally uptaken by cells via endocytosis [8,9]. 
 
Lipid-based nanoparticles 
 
Currently, a wide variety of lipid-based systems is currently described in literature: 
emulsions (e.g. micro- and nanoemulsions, self-micro- and nano-emulsifying drug 
delivery systems (S(M)EDDS)), lipid vesicles (e.g., transfersomes, ethosomes and 
phytosomes) and other systems (e.g., liposomes, solid lipid nanoparticles (SLNs), 
nanostructured lipid carriers (NLCs) and lipid nanocapsules (LNCs)) [10–13]. These 
carriers were first explored for transdermal and topical delivery [14], but rapidly were 
applied for oral, pulmonary and parenteral routes [15]. Due to biocompatibility and 
similarity with cells membranes’ components, lipid-based nanoparticles improve drugs’ 
permeation and cell uptake. Lipid-made systems can be obtained from complex 
glycerides or long-chain fatty acids (e.g. oleic or linoleic acids), which are also 
advantageous to increase drug solubility and absorption, drug loading and ease of 
upgradability to production scale [12,14,16]. 
 
Protein and Peptide-based nanoparticles 
 
Coatings and new targeting moieties such as peptides and proteins are selected to 
promote a target therapy, especially in cancer treatment. Proteins and peptides can be 
attached to the surface of nanoparticles, as targeting ligands, in order to bind selectively 
to specific cell receptors, increasing the efficiency of drug delivery [17]. Therefore, they 
will improve cell uptake, mostly by receptor-mediated endocytosis, and significantly 
decrease the viability of the tumor cells [18,19]. Protein-based corona also improves 
biocompatibility and biodegradability of synthetic polymers as they stimulate the 
clearance of the polymers by enzymatic processes [20].  
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Polysaccharide-based nanoparticles 
 
Polysaccharides are studied as biomacromolecules for drug delivery systems due to their 
high availability in nature, stability, safety and low cost production. As bio-responsive 
polymers, like hyaluronic acid, they respond naturally to physiological variations and are 
fully biocompatible and biodegradable, which make them desirable for drug delivery 
approaches [9,21]. Selection of these materials is related with the capacity of the 
polymeric carrier to show optimal dimensions and chemical properties adaptable to 
biological and pharmaceuticals compounds, through intermolecular associations. As an 
example, hyaluronan-coated nanoparticles were able to interact with epithelial cells via 
CD44 receptor-dependent endocytosis [22,23]. 
 
Metallic-based nanoparticles 
 
Metallic-based and inorganic nanosystems, such as gold nanoparticles, silver 
nanoparticles, silica-based nanoparticles and iron oxide nanoparticles show a great 
flexibility for obtaining systems that comprise different capabilities, as a result of the 
interaction of conduction band electrons associated with formation of nanoparticles [24]. 
In particular, gold nanoparticles appear to be attractive platforms for biomedical 
applications, due to their unique optical properties, chemical stability, easy surface 
functionalization and potentially low cytotoxicity [24,25]. As in cancer therapy, 
functionalized gold nanoparticles show promising results for laser-based treatments, 
such as photothermal and photodynamic therapies, towards cancer cells, preventing 
damage to healthy tissue [26].  
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Abstract 
 
Melanoma is one of the most prevalent and severe type of skin cancer and according to 
the World Health Organization (WHO) data, 132,000 melanoma cases occur every year, 
worldwide. Incidence of malignant melanoma has increased progressively in the last 
decades especially in Australia, North America and Northern Europe. Although earlier 
detection of melanoma increases the recovery prognostic to 80%, this value decreases 
a lot with the occurrence of metastases. Malignant melanoma rapidly spreads to other 
organs and sites of the body, increasing mortality and when ulcerated primary tumors 
develop, the 5-year survival rate greatly drops. Currently, melanoma treatment has 
several limitations, such as a reduced target specificity, severe adverse effects and 
multiple drug resistance. For the past decades, nanotechnology associated with 
sophisticated drug delivery systems allowed higher drug bioavailability, controlled drug 
release, targeting and local drug action, as well as reduced toxicity to healthy tissues. 
Nanosystems made of polymers, metals or natural substances like lipids, 
polysaccharides and proteins can overcome biological barriers and widen the 
possibilities associated with tumor cell targeting or administration route (e.g., topical and 
transdermal routes). Therefore, there is still plenty room for new therapies and 
approaches that can be devised for skin cancer treatment.  
 
 
Keywords: Nanomedicine; Melanoma; Drug delivery; Diagnostic; Treatment.  
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1. Introduction  
 
First described by Hippocrates, malignant melanoma is the seventh most common type 
of cancer in young adults [1]. Melanoma is one of the most prevalent and severe type of 
skin cancer [2], and according to the World Health Organization (WHO) data, 132,000 
melanoma cases occur every year worldwide. Even though recent data is not available 
yet, incidence in 2008 for malignant melanoma increased progressively in the last 
decades, especially in Australia, North America and Northern Europe [3], with an 
estimated 46,000 deaths [4]. Although earlier detection of melanoma increases the 
recovery prognostic to 80%, this value greatly decreases upon development of 
metastases [3], rapidly spreading to other organs and sites of the body, especially to the 
lungs [5,6]. At this stage, resistance to almost every radio- and chemotherapies is high 
[7].  
 
From the main types of skin cancer (i.e., basal cell carcinoma, squamous cell carcinoma, 
Kaposi’s sarcoma, melanoma and Merkel cell carcinoma, by order of prevalence), 
melanoma is originated from the melanocytes of the skin [8]. Melanoma passes through 
a multi-stage process: (I) benign nevi with increased number of nested melanocytes; (II) 
dysplastic nevi with irregular borders, multiple colors, increased diameter and random 
and discontinuous cytological atypia; (III) radial growth phase melanoma with malignant 
cells proliferating within the epidermis; (IV) vertical growth phase melanoma with 
transgression of lamina propria; and finally, (V) metastatic melanoma with spread cells 
to other areas of the skin or organs [3]. Nowadays, it is widely accepted that development 
of dysplastic nevi is associated with an increased melanoma risk [3,9]. 
 
The field of Nanotechnology has contributed extensively towards drug delivery, through 
development of multifunctional drug carriers that allow the increase of drug 
bioavailability, controlled drug release, targeted delivery, as well as a more efficient and 
safer therapy. These systems have grown through a progressive generation of new 
structures, allowing the convergence of new materials, biomolecules, physical and 
chemical techniques, for better outcomes. Under the aim of improving patients’ health 
and compliance for safer and more efficient diagnosis and therapy, these technologies 
broaden the possibilities within the medical field and, in the case of melanoma, may 
overcome issues related with tumor size, vascular structure or the identification of 
specific genomic signatures. One example is how researchers have undoubtedly tried to 
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develop strategies for transdermal drug delivery as a safer solution for skin cancer 
through the application of nanosystems [10–14]. Nanoparticles showed promising 
perspectives, for example, in efficiently penetrating the skin and delivering the drug at 
effective therapeutic concentrations [15]. Hence, development of a local treatment to be 
applied ideally in early melanoma (stage 0/ I), in dysplastic nevi (stage II) or even in 
melanoma stage III, associated to high risk recurrence and need of adjuvant therapy 
[16], could prevent it from reaching melanoma metastatic stage [17]. For other skin 
cancers (non-melanoma), topical and local immunomodulatory therapy is already 
available (e.g., Imiquimod®), which is effective against superficial primary skin tumors 
and cutaneous metastasis [18]. Recently, biphasic vesicles were efficiently used as a 
topical delivery system for alpha-interferon for human papillomavirus infections (e.g., 
Yallaferon®), which has already successfully completed Phase I and II of clinical trials 
[19,20]. In conclusion, there is still much room for new, improved therapies within 
established chemotherapy and radiotherapy, invasive methods (surgery), as well as, 
unavoidable systemic approaches in skin cancer treatment. 
 
 
2. Challenges associated with melanoma issues 
 
Melanoma is a complex cancer that contrasts with other types of cancers in terms of 
evolution and recovery. Mostly melanoma is detected at an early stage and removed by 
surgery; however, before metastases appearance, ulcerated primary tumors grow, 
dropping the 5-year median survival rate from 97% to 39% [3]; by then, patients have a 
life expectancy of 6 to 10 months and the overall survival rate for stage IV melanoma 
(with metastasis) is only 2.3% [21]. Besides, this cancer is associated with multiple 
factors, as demonstrated in Table 1, which aggravate its complexity. 
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Table 1. Internal and external factors related with appearance of melanoma. Adapted 
from [3,16,22]. 
 
Internal Factors External Factors 
Ethnicity 
 
Exposure to UV radiation (e.g., sun, 
tanning-bed) 
Family history 
Occupational chemicals’ exposure (e.g., 
arsenic) 
Fair skin and hair (blonde or red hair) 
History of blistering sunburns at young 
age 
Age of onset (< 40 years)  
Dysplastic nevi  
Immunossuppresion  
 
Melanoma treatment shows limitations related to non-specific targeting, low survival rate 
after ulceration development and high multiple drug resistance (MRD) [2]. Melanoma is 
one of the most complex tumors in terms of tumorigenic stability and molecular 
standardization, which can be both regarded as a great source of difficulty but, at the 
same time, as an opportunity to develop new, specific and targeted treatments. Targeted 
therapies will be explored later in this chapter. Early diagnostic of melanoma based on 
the 1980s “ABCDE rule” (i.e., Asymmetry; Border irregularity; Color variation; Diameter 
< 5 mm; Evolution of the lesion) is used for diagnosis when suspicious lesions appear 
[23,24]. This has improved detection by physicians, based on experience, and, in 
parallel, the study of histological samples by dermoscopy or microscopy has helped 
diagnosis; still, this cannot cover many specific and inner characteristics of the tumor in 
terms of its histological complexity, lack of pattern or molecular identification. 
Consequently, 5-10% of melanoma cases are reported to be difficult to diagnose [23]. 
Also in 88-89% of the cases, no additional metastases are discovered within the analysis 
[21].  
 
Melanoma risk increases with the number and size of atypical nevi in skin [3,9]. 
Monitoring atypical nevi, especially in people prone to develop melanoma is, therefore, 
crucial; however, it is difficult to establish said association by only conducting histological 
examination. Molecular phenotyping shows a big role in distinguishing common nevi and 
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dysplatic nevi that can be related to melanoma appearance. Atypical nevi show higher 
proliferation than common nevi, as well as the presence of reactive oxidative species, 
although molecular markers are still unknown or too similar to differentiate. 
  
One of melanoma’s complex characteristics is the enormous quantity of receptors 
involved in the development of this cancer. There is still a lot left to know about the 
presence of receptors, molecules and factors involved in melanocytes’ growth, 
differentiation and migration in the skin [5]. The behavior of melanoma treatment 
resistance is also not clear yet [7]. Refractory response and MDR of cancer are 
associated with genetic and molecular heterogeneity that results in complex biological 
mechanisms for multiple and different subpopulations of cell pools within the same 
tumor. For example, ATP-binding cassette B5 (ABCB5)-overexpressing cells increase 
along with tumor aggressiveness, after the first treatment attempt (e.g., dacarbazine, 
vemurafenib and doxorubicin). In addirion, these cells are accompanied by drug efflux 
properties in several melanoma cell lines, which increase resistance to chemotherapy in 
advanced stages of the disease. Until now, it was thought that melanoma cells showed 
enhanced tumorigenecity with stem cell-like properties, meaning that some of these cells 
had the ability to renew themselves and alter their aggressiveness as a whole identity.  
However, it seems that melanoma does not follow a cancer stem cell model, showing a 
high degree of plasticity, which results in switching between different stages of 
proliferation and malignancy (interconversion). Thus, metastatic melanoma may contain 
a high proportion of cells with intrinsic tumorigenic potential that may not be detected in 
follow-up assays [25]. 
 
Finally, another issue in melanoma’s progression is the chronic inflammation already 
demonstrated for colorectal carcinoma, esophageal adenocarcinoma and Marjolins’s 
ulcers [18]. Inflammatory processes play a role in all of the main stages of cancer, namely 
initiation, proliferation and invasion, as tumor cells produce cytokines and chemokines 
to attract immune cells that infiltrate into the tumor tissue [26]. Chemokine receptors 
regulate migration of leukocytes and play a role in infection and inflammation. It is also 
important to find the inflammatory gene expression profile in melanoma since it can work 
as a useful biomarker for response to vaccines and other immunotherapies [21]. Besides, 
melanoma cells show high expression of glucocorticoid receptors [27,28] and, therefore, 
targeted glucocorticoid-based therapy could also be selected to treat this immune-
related cancer by inhibiting tumor growth [29], reducing the negative effects and 
controversy associated to this therapy. New molecules are currently being explored and 
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specifically plants with known anti-inflammatory and anti-tumor actions (e.g. 
polyphenols) [26], and seem to be a good source for new therapeutics. However, most 
of these molecules may exhibit difficulty in targeting melanoma, prompting the use of 
nanoparticles for these advanced therapies. This has been driven by key events of 
scientific evidence on their ability to overcome the ineffectiveness of many cancer 
treatments, prevent side effects and be able to detect early cancer that would not be 
identified by other means (Figure 1). For example, camptothecin, an alkaloid with anti-
tumor action extracted from Camptotheca acuminate, with poor solubility and limited 
bioavailability, was incorporated into polymeric polyethylene glycol - poly(lactic  acid) 
(PEG-PLA) nanocapsules, with high encapsulation efficiency (> 80%) for treatment of 
melanoma lung metastasis, demonstrating better results as in vivo compared to free 
drug, plain PLA nanocapsules and untreated tumor [30].  
 
 
 
 
Figure 1. Multiple actions of nanoparticles in melanoma improve survival rate. 
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Targeting melanoma cells 
 
Advances in molecular cancer biology have led to an increasing the knowledge of tumor 
receptors and ligands. As regarded before, melanoma is a heterogeneous cancer with 
different genetic patterns for each melanoma subtype [31], which have been reviewed 
extensively [5,32,33]. In order to effectively treat melanoma, a targeted inhibition of key 
points in molecular and biological mechanisms of tumor cells may be the most effective 
solution ahead. There are several pathways that can be targeted for disruption: cell 
proliferation (growth) and differentiation, angiogenesis, invasion (metastasis) and 
apoptosis [5,33]. By understanding the molecular basis behind these pathways, we may 
go further in unraveling the mechanisms by which chemo- and radiotherapy resistance 
occur and how can we beat this type of cancer [5,33]. We may find interesting to try a 
combined approach – simultaneously targeting multiple signaling cascades – or by first 
doing a molecular trial to identify the main targets characteristic to a given tumor. Herein, 
we will focus only on the most important receptors and those that are well described, 
understanding that there are many others involved in melanoma development. 
 
Melanocytes’ proliferation occurs coupled with that of keratinocytes, which regulate their 
growth and receptor expression profile at their surface, via cell adhesion and growth 
factors (e.g., cadherins, growth factors and endothelins). One of the most important 
receptor is melanocortin receptor 1 (MC1R), regulated by melanocortins, such as α-
melanocyte-stimulating hormone (α-MSH), adrenocorticotropic hormone (ACTH) and β-
endorphin [34]. MC1R is expressed in high levels in the majority of melanoma cell lines 
and at low levels in normal cells (i.e., keratinocytes, melanocytes, fibroblasts and 
immunologic cells) [34,35]; besides, MC1R may play an important role in immune and 
inflammatory processes: although expressed in lower levels than in both cutaneous and 
uveal melanomas (α-MSH binds up to 5 times more to melanoma), this receptor appears 
significantly in activated monocytes [36]. The ligand α-MSH confers attachment and 
internalization to MC1R overexpressed on the surface of melanoma cells, 
simultaneously reducing the metastasis growth, but also diminishing the immune 
response against melanoma [37,38]. MC1R is also responsible for stimulating eumelanin 
synthesis in melanocytes, which protects the skin from UV radiation and the damage it 
can cause in DNA [39,40]. Studies made with gold nanospheres covered with PEG and 
displaying an agonist targeting moiety against MC1R achieved a successful targeting 
with high doses at the tumor site, which after laser treatment, induced high levels of 
necrotic tissue therefore having efficient photothermal ablation ability. Gold nanoparticles 
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were selectively taken up by the cell even reaching the cytoplasm [41]. In addition, an 
agonist moiety targeting (α-MSH analog) also shows superior internalization by tumor 
capillaries, suggesting a receptor-mediated endocytosis, while antagonist targeting stays 
at the cell surface, since it cannot mediate endocytosis [42]. In another study, 
Polyethylene glycol-coated (PEGylated) protein nanoparticles formulation based on 
human ferritin were developed and functionalized with α-MSH through a link created by 
genetic modification with increased specific binding to melanoma cells. In vivo 
administration of these nanoparticles in mice also demonstrated higher accumulation 
into cutaneous tumor as compared with other organs (e.g. liver) [43].  
 
Mutations in MC1R receptor are related to melanoma proliferation: this highly 
polymorphic receptor affects the response to UV light by melanocytes increasing the 
DNA damage effects. A recent study found that α-MSH is useless in absence of MC1R 
expression, increasing the risk of melanoma; also, activation of the p53 pathway by α-
MSH can work as a preventive strategy against DNA damage [39]. Desai et al. (2013) 
showed successful tumor regression in mice that received a melanoma xenograft, upon 
intraperitoneal administration of complexes of danaciclib- 2-hydroxypropyl-β-
cyclodextrin (HPβCD). In vitro 2D adherent and 3D organotypic melanoma models 
revealed a positive response to the administration of the complexed drug, with inhibition 
of cell growth, depending on p53 signaling [44]. In fibroblasts, for example, cellular 
growth seems to be compromised after α-MSH stimulation, but in presence of 
polymorphisms, proliferation occurs [35]. Recently, as fibroblasts present this metabolic 
support to melanocytes, including when melanoma cells are formed, new targets based 
on overexpression or knock-down of key metabolic genes have been validated, for 
promoting tumor growth and /or metastasis in mice models [45]. Melanoma cells also 
activate fibroblasts and, in return, these cells provide them both structural (i.e., 
extracellular matrix proteins that increase tumor cells survival) and chemical support (i.e., 
growth factors) [34]. Interactions between melanoma and stromal cells through the 
microenvironment promote the tumor growth, malignancy and also drug resistance. 
Melatonin receptors are also important since they regulate the phenotypic actions of cells 
growth and differentiation [5]. Lipid-polymeric nanoparticles for melatonin transdermal 
delivery were applied to treat early stage melanoma [46,47]. Melatonin is a suitable 
molecule for transdermal and topical transport and could benefit from the advantages of 
a nanoparticulate system, such as controlled release, targeted action and deposition on 
specific cell pools in the skin.  
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Also present in the signaling pathway, protein WNT5A expression increases with 
melanoma progression; present also in common nevi, it is related to melanoma 
aggressiveness, motility and invasion of cutaneous melanoma [48]. Extracellular-signal-
regulated kinase (ERK) is the only known activated protein by Mitogen-activated protein 
kinase kinase (MEK 1/ 2), which influence on melanoma is still unknown. Still, higher 
levels of ERK are identified in subcutaneous metastases compared with lymph node 
metastases or common nevi, indicating that protein activation occurs at advanced 
melanoma stages. Insurgence of medicines to inhibit MEK 1/2 is, therefore, promising 
for these kinds of tumors [33], since it is overexpressed in the majority of melanomas 
[21]. Other markers help in clinical diagnosis by accurately distinguishing melanoma 
cases from dysplastic nevi ones, showing some progress, in spite of the cancer 
complexity [49]. The majority of melanomas (50-60%) also show an active mutation 
(V600E) for B-Raf proto-oncogene (BRAF), inducing tumor cells growth and 
angiogenesis. Thus, therapy with BRAF inhibitors is also promising [31,33]. Vemurafenib 
(per os) shows a 30-fold selectivity for the pV600E mutated form compared with wtBRAF. 
But, this drug causes keratoacanthomas and invasive cell carcinoma, treatment 
resistance and melanoma relapse [31]. MEK and phosphoinositide 3-kinase (PI3K) 
pathways also interfere in BRAF mutations and, as targets for melanoma, can reinforce 
the idea of conjugated bitherapy in this type of cancer [26]. Uveal melanoma causes 
metastases mainly (95%) in the liver and lack mutations of the BRAF gene, which 
indicates that it acts by different signaling cascades than cutaneous melanoma (e.g., 
MEK/ MAPK), mainly mutually exclusive GNAQ or GNA11 mutations. However, BRAF 
(V600E) mutation could be identified in small populations of cells within the uveal tumor. 
Other ocular tumors that not arise from uvea are biologically similar to cutaneous 
melanoma [50]. 
 
Finally, vitamin D3 receptors may also be an interesting alternative to explore for a 
possible role in anti-melanoma mechanism [5]; tyrosine is also an interesting target, 
since melanoma needs higher concentrations of this amino acid residue to proliferate. 
Specific targeting is highly valuable and can affect the biodistribution. PEG-PLA 
nanocapsules delivering a modified form of tyrosinase enzyme improved its stability for 
more time at body temperature, in order to lower the systemic tyrosine available for 
melanoma [51]. This approach can also benefit from the different scale sizes since 
smaller particles (< 100 nm) can enter melanoma cells and inhibit proliferation and 
invasion, but larger particles (> 200 nm) can also convert tyrosine, lowering the levels in 
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the extracellular environment and acting by following the same path as the metastases 
[52].  
 
 
3. Nanotechnology and progress of drug delivery systems 
 
As the nanotechnology field grows, with almost 40 years of study, employment of new 
mechanisms to reach specific targets is now on its way. In terms of cancer (with the 
same years of study), we can see that a lot has been done to overcome the drawbacks 
of this disease, as more complex and unpredictable cancers are occurring [53]. 
Melanoma is considered one of the most challenging cancers, in terms of diagnosis and 
treatment efficacy. Enhanced knowledge of biomolecules and polymers, as suitable 
structures for drug transport, improve the performance of those drug delivery systems. 
Throughout the studies over the last years, physical and chemical characteristics of 
commonly used biomaterials have been described and the pros and cons demonstrated 
[54–57]. By working with different materials it is possible to tune their interaction with 
biological environment. Interactions between materials are also being studied, and they 
may occur by simple electrostatic interactions or by reactive promoted links, such as 
covalent ligations. Interactions with drugs can also be used, as both slow or fast release, 
obtained directly by adsorption at the particle surface, might also be required [58]. All 
these facts are currently background knowledge for the seeking of hybrid nanocarriers. 
Also, there is a main importance in the use of biomolecules and natural ligands that can 
mimic natural cell responses and mechanisms, facilitating the active compounds 
entrance and avoiding their rapid clearance [59]. It is also accepted that binding ligands 
at the surface of the nanoparticles facilitate their penetration through the biological 
barriers to reach the specific targets (e.g., BIND-014) [60]. Especially for hydrophobic 
substances with anti-tumor and anti-inflammatory activities, these systems work as a 
promising solution for poor drug bioavailability and also offer other ways to enter the 
body, such as pulmonary, ocular or transdermal routes [61]. Solid tumors, like 
melanoma, have a pore cut-off between 380 and 780 nm [59], so particle size is an 
important factor, as nanoparticles with 200 nm cannot escape the normal vasculature, 
but accumulate in cancer vicinity, due to extravasation and diffusional barriers [59]. As 
will be further explained in this chapter, with the help of nanotechnology we may be 
closer to the desirable personalized cancer therapy. 
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4. Nanomedicine applied to melanoma prevention 
 
One of the main problems associated to poor survivability of patients with melanoma is 
the difficulty of early diagnosis. Clinical and self-examination for high risk patients is the 
first way for prevention. In spite of physicians’ experience, we may be facing a 
remarkable development with the advent of molecular identification and genetic typing, 
for improved diagnostic of cancer. Another important advance is the use of imaging 
techniques that permit a clear visualization of the skin distinguishing different 
morphologies and depths of dysplastic nevi. In conjugation with fluorescent markers, 
incorporated within small sub-micron particles, we may be able to target specific 
receptors and proteins on the tumors’ surface, facilitating its identification. There is 
already some work in this field, especially with metallic-based nanoparticles as 
multifunctional systems. For example, the use of ultrasound imaging to follow the 
progression of tumors can work for diagnostic and therapy associated with drug delivery 
systems [62]. Gold nanoparticles can be used as contrast agents in photoacustic imaging 
(PAI), which is based on the delivery of non-ionizing optical pulses at near-infrared (NIR, 
650-900 nm) for an accurate and early diagnosis of melanoma. These techniques will be 
further explained. 
 
 
 
Figure 2. Gold nanoparticles’ mechanisms in melanoma prevention. Diagnosis by near 
infrared (NIR) light activation and targeting penetration into melanoma cells, by 
photosensitizers and fluorescent dyes, for further molecular plotting.  
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Chemoprevention of melanoma, described elsewhere, suggests the use of targets for 
effective delivery of anti-tumor agents (e.g., statins, curcumins, selenium, non-steroid 
anti-inflammatory drugs (NSAIDs) and vitamin D) [63]. Most of them act hypothetically 
by inhibition of proliferation and invasion of melanoma. One example is the use of 
selenium supplementation as its antioxidant properties are described to prevent 
melanoma appearance, when used topically (twice a week) at an early stage; however, 
this activity is still controversial as it may aggravate the tumor growth in an advanced 
stage [64]. Another study conducted with a derivative of selenium with nitric oxide 
synthase (iNOS) inhibitor demonstrated that topical application was not aggressive to 
keratinocytes or dermal fibroblasts and decreased the tumor growth in vitro (70-80%) 
and in vivo (approx. 50%), by promotion of the tumor cell apoptosis [65]. In fact, as 
described in other papers, the use of selenium nanoparticles can promote a targeted 
activity and higher concentration at the tumor site, reducing possible adverse effects 
behind the controversial results. Selenium nanoparticles have also been tested as 
carriers for anti-tumor drug 5-Fluorouracil (5-FU), physically adsorbed at the surface, in 
order to obtain a synergistic effect and reduce the chemotherapy adverse effects. The 
authors also proposed the use of this system as a topical formulation in order to avoid 
the in vivo degradation of 5-FU- selenium nanoparticles and to reduce the non-target 
toxicity [66]. Finally, hyaluronic acid (HA) is described in the literature as both drug carrier 
and target ligand due to its affinity to CD44 receptors in cancer cells [67]. Spherical 
nanoparticles with a size less than 200 nm and a high negative surface charge 
demonstrated a receptor-mediated endocytosis for melanoma cell lines and reduced 
significantly the tumor growth in mouse models after intra-tumor (i.t.) and intravenous 
(i.v.) injections [67].  
 
Photoprotection 
 
Exposure to sunlight, the main environmental factor behind melanoma, and skin cancer 
in general, is still not completely described in terms of the exact influence of the 
wavelength and UV-B/ UV-A light on melanoma [68]. Although for many years this could 
not explain the appearance of melanoma in different body regions (e.g., brain, lung or 
vagina), or even the appearance of cancer in non-Caucasian people, it is clear that there 
is a relation between the disease and this risk factor. Recent studies have gone further 
in this investigation and found a relationship between the formation of cyclobutane 
pyrimidine dimmers – damaging the cells’ DNA – and leading to tumor initial 
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development, as well as other unidentified bulky lesions mainly associated with UV-B 
light [69]. Nanoparticles also have an important impact in this field, as they serve as 
effective photo-protective carriers applied to cosmetic formulations, especially zinc oxide 
(ZnO) and titanium oxide (TiO2) nanoparticles [53], reaching effectively the skin surface 
cells with sunscreen and protecting them from the damage action of UV light.  
 
Tumor imaging and detection 
 
Long goes the time where surgical management occurred according the Handley’s 
principle of removal of 5 cm of the subcutaneous tissue for metastatic melanoma. Even 
narrower margins (1 cm for melanoma ≤ 1mm and 2 cm for thicker melanoma) are now 
supported by imaging techniques. Based on their colorimetric and fluorescence 
properties, nanoparticles may facilitate the localization of the tumor cells, minimizing the 
extent of skin removed from surgery. Nanoparticles can also identify other tumors 
dispersed within the body, if ulceration or metastases occur. For example, paramagnetic 
nanoparticles containing a targeting moiety to αvβ3 integrin were used to detect early 
angiogenesis formation of early melanoma tumors [70]. This technology is valuable to 
avoid invasive approaches, as the majority of the relapses are also local (50-85%) during 
the first two years [71]. Confocal laser scanning microscopy (CLSM) is a useful imaging 
tool in distinguishing common nevi, dysplastic nevi and melanoma, through differences 
in cell morphology and loss of keratinocyte cell borders [72], as well as optical coherence 
tomography (OCT) similar to B-mode ultrasound pulse-echo imaging. Melanoma often 
appears with deformed borders of the dermis and spike morphology when compared 
with common benign nevi [68]. OCT also estimates the superficial thickness of the skin 
cancer, but cannot yet differentiate states of inflammatory processes or cancer [68]. 
High-frequency ultrasound (20 MHz) is also used in diagnosis of lesions close to the skin 
surface (epidermis and dermis) and other techniques including Terahertz Pulsed 
Imaging (TPI), Magnetic Resonance Imaging (MRI) and Raman Spectroscocpy (NIR, 
650-900 nm) can also evaluate skin structure in relatively safe conditions [68]. Since 
biological tissues and fluids do not absorb the red wavelength range [73], light can 
penetrate deeper into the skin layers [74]. Most anatomical imaging techniques do not 
require contrast agents, but molecular ones do. Photon Emission Tomography (PET) 
and Single-Photon Emission Computed Tomography (SPECT) are, nowadays, widely 
used for the diagnosis of cellular and molecular specificities. Several targeting peptide 
probes using radio-isotopes that do not block the receptor binding are being developed 
to improve these imaging techniques. Development of radio-labeled α-MSH can improve 
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the diagnostic of melanoma, especially as cyclic analogs with higher stability in 
physiological conditions, improved pharmacokinetics and superior in vivo tumor targeting 
[75]. Cyclized α-MSH peptide derivatives can also be used for melanoma imaging and 
radiotherapy, since they can get higher binding activity, tumor cells’ uptake and good 
imaging properties [76]. In terms of nanotechnology application, the most used systems 
are magnetic iron oxide nanoparticles (IONPs), quantum dots (QDs), polymeric 
nanoparticles and carbon nanotubes [75]. Nanoparticles, besides their small size and 
capacity to penetrate the cells, can be linked to multiple probes and targeting ligands by 
surface functionalization, improving the imaging of cellular and molecular subjects. For 
example, arginylglycylaspartic acid (RGD) was linked to partially thiolated 
polyamidoamine (PAMAM) G4 dendrimers coating cadmium selenide (CdSe) QDs to 
reach melanoma cells that overexpress 𝛼v𝛽3 integrin in their vessels. With a final size 
of 13.5 nm, QDs were useful for detection, while dendrimers were used to confer the 
desirable surface properties and link the intended residues. Both in vivo and in vitro 
uptake was associated to the binding of RGD to the integrin receptor while no passive 
targeting was observed after three hours [77]. Cases of inflammatory regions could be 
counteracted by nanotechnology application and targeted delivery of fluorescent drugs, 
avoiding other invasive methods [74,75]. 
 
Theranostics  
 
In terms of diagnostic and detection, nanoparticles can function as both tumor markers 
and as carriers for photodynamic substances. Metallic particles made of gadolinium, 
nickel, iron and gold can be used as contrast agents and as standards for these 
approaches, which are regarded as safe and can work together with other techniques 
such as ultrasounds, laser or thermal therapies to destroy tumors. Commonly, liposomes 
and polymersomes are selected [78], mainly because these vesicles can easily penetrate 
the cell interstices and reach the tumor site. They can also incorporate highly 
hydrophobic drugs for therapy and hydrophilic molecules/ probes normally selected for 
imaging [78], as mono- or bitherapy. Nanoparticles are the most used systems for 
theranostics purposes, especially after increased stability by coating the particles’ 
surface with ligands or molecules (e.g., peptides, carbohydrates, oligonucleotides), 
which also serve a therapeutic action [73]. This fact broadens our possibilities in terms 
of the applications, as these particles are suitable for visualization of living cells and all 
dynamic processes occurring in them, combining different probes to stain different 
locations on the cell surface and within the cell. Still, very small gold nanoparticles (1-2 
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nm) show high toxicity due to the possible irreversible binding to DNA molecules [73]. 
Silica has gradually gained its space in the field, as this polymer is highly stable, 
biocompatible, with a strong potential in terms of particle functionalization and drug 
release [79]. New ligands or modification of existing ones can be used to improve the 
binding affinity and activity. One example is the development of peptides with single, 
double and triple bonds harboring lysine residues and other moieties, for cells 
overexpressing MC1R. It was found that trivalent ligands can reach higher selectivity and 
better affinity in presence of high density receptors [80]. This approach could offer 
promising tools for both diagnosis and therapy in melanoma. Finally, a different approach 
of theranostics is the use of imaging nanoparticles for drug follow-up during treatment. A 
study focused on the distribution of paclitaxel in solid tumors, such as melanoma, by the 
use of TiO2 nanoparticles coupled with imaging techniques (mass spectrometry imaging, 
2D) that show some drawbacks, like high background noise and presence of 
endogenous molecules that mask the signal; nanoparticles improved the resolution due 
to their physical behavior for localized uniform deposition of energy, being used as a 
matrix for imaging. Therefore, it was possible to visualize the drug presence in the central 
portions of the tumors, after different treatment schedules [81]. 
  
 
5.  Nanomedicine applied to melanoma treatment  
 
Most melanoma-related advances have been made at the level of treatment 
development [82]. Nanomedicine appears as an alternative to traditional therapeutics 
that combine an ineffective action and systemic side effects, associated with the 
destruction of both tumor and healthy cells. There is also a possibility to combine different 
approaches and new molecules (e.g., monoclonal antibodies (mAb)) at the particle 
surface, since melanoma is essentially an immunogenic tumor, and encapsulate an anti-
tumor drug to effectively destroy the cancer. To this matter, PAMAM G2 linked with 
octavalent N-acetyl-glucosamine showed ex-vivo enhanced T-cell and natural killer cell 
activity, which may explain the resulting in reduced tumor growth and enhanced mean 
survival time in a dose-dependent manner in vivo [83]. The complexity of the disease 
shows that higher selectivity and specificity have to be fulfilled with the selected 
treatment. Therapeutic agents have to be determined for each person or each type of 
cancer. Until now, few drugs have been approved by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) for melanoma treatment (Table 2).  
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Table 2. Approved drugs by U.S.A. and European Agencies for melanoma treatment 
(Food and Drug Administration (FDA), 2016, at http://www.fda.gov; European Medicines 
Agency (EMA), 2016, at http://www.ema.europa.eu). 
 
Therapy Type of agent FDA approval EMA approval 
Chemotherapy Akylating agents 
Dacarbazine 
(1970) 
Dacarbazine 
(2002) 
Immunotherapy 
Oncolytic herpes 
virus 
Talimogene 
Laherparepvec “T-
Vec” (2015) 
Talimogene 
Laherparepvec “T-
Vec” (2015) 
Monoclonal 
antibody anti-PD-1 
Pembrolizumab 
(2015) 
Pembrolizumab 
(2015) 
Monoclonal 
antibody anti-PD-1 
Nivolumab (2014) Nivolumab (2015) 
Antiviral 
PEGinterferon alfa-
2b (2011) 
- 
Monoclonal 
antibody anti-
CTLA4 
Ipilimumab (2011) Ipilimumab (2011) 
Interleukins 
Aldesleukin, IL-2 
(1998) 
- 
Antiviral 
Interferon alfa-2b 
(1986) 
Interferon alfa-2b 
(2000) 
Targeted therapy 
BRAF V600 
mutation / MEK 
inhibitors 
Cobimetinib (2015) 
*used in combination with 
vemurafenib 
Cobimetinib (2015) 
Trametinib (2013) Trametinib (2014) 
Dabrafenib (2013) Dabrafenib (2013) 
Vemurafenib 
(2011) 
Vemurafenib 
(2012) 
 
Nanomedicine can also help to accomplish this approach and reach the complexity of 
each cancer, such as combining different therapeutic agents. One suggestion is the 
association of anti-CTLA4 ipilimumab and BRAF-inhibitor vemurafenib to improve intra-
tumor infiltration by acting synergistically to avoid the immunosusceptibility of the tumor, 
since ipilimumab increases the overall survival of melanoma patients [21].  Ipilimumab 
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was actually the first agent to reach this positive reaction in cases of advanced 
melanoma and conjugation approaches are already in phase II for clinical trials (Table 
3). This drug is proposed for patients with refractory and advanced melanoma stage and 
has demonstrated overall improvement of patients’ survival, but cause immune related 
reactions that are counteracted by administration of glucocorticoids and other 
immunosuppressants [6,84]. Another important strategy includes mAb and anti-
angiogenetic drugs (e.g., paclitaxel and docetaxel) [21]. This approach can also be 
improved by nanotechnology as demonstrated for docetaxel incorporated into lipid-
based nanomicelles (20-25 nm) [85] and into solid lipid nanoparticles (SLN) (140-180 
nm), including a variety of lipids for better hydrophobic drug incorporation, tolerability and 
cell transport [86].  
 
Dendrimers are another class of polymeric nanoparticles with a promising application in 
cancer diagnostics and therapeutic [87,88]. By virtue of their small size and large number 
of functional terminal groups, dendrimers are highly favorable to interact with biological 
systems at molecular level. Since their surface chemistry is one of the key critical 
elements between therapeutic value versus toxicity, specialized moieties can be 
precisely attached to increase molecular targeting (e.g., attachment of antibodies, folate 
or RGD), to avoid unspecific interaction with cellular components (e.g., by cationic 
charges) or with reticuloendothelial system (RES), as well as to increase the residence 
time by attachment of PEG. The architecture, composition and size of the polymer may 
also influence the cell uptake and, therefore, the therapeutic effect [89,90]. Dendrimers 
show a protein-like structure, so they can also have therapeutic activity of their own. For 
example, Poly(L-lysine) G6 dendrimers were shown to have anti-angiogenic activity both 
in vitro and in vivo in B16F10 model after i.v. administration at a dose of 50 mg/kg/day, 
being able to delay tumor growth while increasing apoptosis [91].  
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Table 3. Current clinical trials studies associated with nanosystems (U.S. National Institutes of Health, 2013-2016, at 
http://clinicaltrials.gov). 
 
Systems Subject Melanoma stage – Clinical stage Reference 
Inorganic 
Nanoparticles 
Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel 
Lymph Node Mapping Head and Neck Melanoma Head and Neck Melanoma - Phase 0 NCT02106598 
Protein-based 
Nanoparticles 
Paclitaxel Albumin-Stabilized Nanoparticle Formulation (and Bevacizumab 
or Ipilimumab) as First-Line Therapy 
Stage IV inoperable - Phase II 
(completed) 
NCT01879306 
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-
Stabilized Nanoparticle Formulation and Carboplatin 
Stage IV inoperable - Phase II 
(completed) 
NCT00626405 
Paclitaxel Albumin-Stabilized Nanoparticle Formulation (nab-paclitaxel, 
Abraxane®) 
Intraocular melanoma inoperable - Phase 
II (completed) 
NCT00738361 
Paclitaxel Albumin-Stabilized Nanoparticle Formulation (ABI-007) 
Inoperable locally recurrent or metastatic 
melanoma - Phase II (completed) 
NCT00081042 
Carboplatin and ABI-007 (Abraxane®) 
Stage IV melanoma inoperable - Phase II 
(completed) 
NCT00404235 
Abraxane and Avastin 
Metastatic malignant melanoma - Phase 
II (completed) 
NCT00462423 
BIND-014 Advanced or metastatic cancer - Phase I NCT01300533 
Liposomes 
Liposomal Cytarabine in combination with Radiotherapy and Lomustine for 
treatment of Leptomeningeal Metastasis from Malignant Melanoma 
Advanced or metastatic melanoma - 
Phase I 
NCT01563614 
Vincristine Sulfate Liposomes Injection (Marqibo®) 
Malignant melanoma – Phase I 
(completed) 
NCT00145041 
Vincristine sulfate liposomes injection (Marqibo®) 
Metastatic malignant uveal Melanoma – 
Phase II (completed) 
NCT00506142 
Liposomal Vaccine (Lipovaxin-MM®) Melanoma – Phase I (completed) NCT01052142 
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b 
Metastatic (stage III) cutaneous 
Melanoma – Phase II (completed) 
NCT00004104 
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Radiotherapy 
 
Radiotherapy is based on radiation use for cancer cells destruction. However, this 
treatment is very complicated and dreadful for patients, who suffer from several side 
effects, and is rarely used only as monotherapy. Based on this fact, we can bring together 
the two approaches (radio- and chemotherapy) and, for example, administer anti-tumor 
drugs encapsulated inside nanocarriers that respond to the action of lasers or radiation. 
Metallic-based nanoparticles release anti-tumor drugs only after reaching the tumor site, 
by means of a radiation beam, or after thermal ablation, acting as a synergistic 
multifunctional therapy for cancer [74].   
 
High-frequency ultrasound (HFUS) imaging creates a B-scan image of the tissue 
evolution after tumor implementation in melanoma orthotopic models [92]. 
Electrochemotherapy (ECT) is a new technology that combines electric pulses (non-
thermal) and anti-tumor agents (e.g., bleomicin). External electrical stimulations increase 
the cells permeability and facilitate drug penetration into the tissue. However, it shows 
side effects such as erythema, erosion or ulceration (scaring) and oedema and pain [21]. 
Still, in a long-term response (5 years) study, made on patients having malignant 
melanoma (refractory or relapsed cutaneous melanoma), and treated with ECT, it 
showed that approximately 50% of the patients displayed a complete response and were 
free of the disease after two years [1].  
 
Photodynamic therapy (PDT) is a non-invasive procedure including a photosensitizing 
drug (e.g., prodrug 5-aminolevulinic acid named as 5-ALA) that can be activated by light 
to produce oxidative reactions locally and destroy the tumor cells [74,93]. Light is 
obtained through a laser that can emit pulses; metallic nanoparticles improve PDT by 
focusing the beam to a localized area, minimizing eventual damage to adjacent normal 
cells and by triggering drug release only on the tumor site. This technique may be used 
in all areas of research, diagnosis, prevention and treatment. Laser-based therapies 
already approved as topical treatment by FDA and EMA for non-melanoma cancers and 
previous lesions like actinic keratosis, can also allow combination of treatments, through 
the use of targeting agents (photosensitizer plus immunomodulator) or, more recently, 
coupled with nanoparticles to increase the penetration of the photosensitizers deeper 
into the skin. Actually, PDT allied to nanomedicine could revolutionize dermal melanoma 
treatment by applying non-invasive local therapies, with minimal side effects [74], and 
also reduce the thermal dose required for cytotoxicity that affect both cancer and healthy 
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tissue, since the two techniques work synergistically together [94]. For example, by 
assessing the effectiveness of two model sensitizers used in PDT (meso-tetrakis[4-
sulphonatophenyl]porphine,TPPS4 and its zinc metallocomplex, ZnTPPS4), in the 
presence and absence of Hydroxypropyl-β (HPβ)-CD, both compounds revealed >1.2 
fold decrease in IC50 when complexed with CDs [95]. And, in a follow-up work [96], the 
same authors showed that binding the same sensitizer to HPβCD improves its cellular 
uptake and induces DNA damage on melanoma cells, at a relatively low radiation dose. 
Multifunctional particles for melanoma-target drug delivery become evident for a role in 
this part, meaning above that all different approaches and, with them, different materials, 
such as complex organization of organic, inorganic molecules, biological agents and 
polymers, are stably conjugated for specific goal. Poly(lactic-co-glycolic acid) (PLGA) 
coated magnetite nanoparticles, further incorporated into a thermosensitive polymer 
revealed a slowly release of curcumin (anti-tumor model drug) for more than 25 days, 
depending on temperature and polymer degradation. These particles also showed a 
targeted accumulation in the tumor cells, after application of a magnetic field on the tumor 
site. Polymeric coating seems to reduce the toxicity of these systems, while preserving 
their magnetic properties [2]. 
 
Modular nanotransporters (MNTs) are developed based on natural cell mechanisms 
(e.g., polypeptide that mimics cell transportation and attachment) and can be improved 
by surface modification with α-MSH for a targeted delivery of the photosensitizers to the 
melanoma cells. This method accomplished 93% inhibition of melanoma proliferation 
and increased mice lifespan, comparing with the ones treated with the free 
photosensitizer [97]. The same system tested with Epidermal Growth Factor (EGF) for 
other tumors demonstrated a broad variety and flexibility of these transport systems [98]. 
Targeting moieties also improve the treatment results due to reduction of effectiveness 
caused by melanin light absorption and increased in two-fold the median survival of the 
mice, significantly inhibiting tumor growth. Selecting the most appropriate targeting 
moieties is, therefore, important to conjugate with the microenvironment and molecular 
mechanisms associated with the tumor before and after thermal damage [94]. Smaller 
particles (20-200 nm) with longer half-lives (e.g., surface modification with PEG) seem 
to have the desirable characteristics for an efficient tumor targeting. As for possible 
targeting moieties, anti-CTLA4 antibodies and tumor necrosis factor alpha (TNF-α) 
appear to be good candidates, as well as compounds that reduce the hyperpermeability 
threshold of cell membranes (e.g., antioxidants or anti-inflammatory agents) and that 
facilitate the anti-tumor drug entrance into the cancer cells [94]. 
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Figure 3. Different approaches applied to photodynamic therapy. Nanoparticles can 
enter the cells and reach the cytoplasm through targeting moieties at the surface and 
promote PDT by focusing thermal ablation and laser action to the tumor site. 
 
 
Chemotherapy 
 
In chemotherapy, nanotechnology has played a significant and distinctive role over the 
last 20 years. Along with many studies, there is a consensus that small nanocarriers 
between 10 and 100 nm can penetrate into the tumor vasculature, reaching the tumor 
cells by a target- effect. Also, nanocarriers are an interesting mean for new molecules 
and compounds with anti-tumor activity. Normally, these substances show a poor 
solubility and then bioavailability, as they have a lipophilic character and high molecular 
weight. Transport via nanocarriers facilitates the substances’ penetration by endocytosis, 
aiming a more effective action. Another advantage is the possibility of bitherapy: one 
active agent encapsulated inside the core and another adsorbed at the surface of the 
carrier, for a synergistic treatment approach. Finally, nanoparticles can facilitate the 
administration of chemotherapy agents that is, through i.v. injections sometimes seen, 
as a disadvantage for the patient. Controlled drug release and the broad possibilities for 
incorporation into other pharmaceutical formulations, for administration through other 
routes, can ease this great difficulty for both clinicians and patients, aiming an 
independent and secure chemotherapy [99]. 
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Figure 4. Nanomedicine applications in melanoma treatment for improvement of local 
efficiency and, ultimately, patient compliance. 
 
An example of how nanotechnology can implement several approaches in one system 
is the use of polymeric PLA particles to carry the anti-tumor drug, dacarbazine, and 
immunotherapeutic agent for TRAIL-receptor, DR5, related with the tumor necrosis 
factor family, inducing apoptosis in melanoma cells overexpressing this receptor. The 
mAb was dispersed onto the nanoparticles surface, which was confirmed by 
fluorescence techniques. Binding and specificity of nanoparticles were very important for 
the tumor cytotoxicity increase, since it promoted the entrance of dacarbazine by 
receptor-mediated endocytosis. Particles showed a size smaller than 200 nm and a zeta 
potential of -30 mV [100].  
 
In another study, PAMAM dendrimer of different sizes (G2, G3 and G4) were conjugated 
with oregon green and compared to linear and branched polymer polyethylenimine (PEI) 
for their uptake on B16F10 melanoma cells. The mechanism of absorption for the 
PAMAM G4 was found to be cholesterol-dependent since a reduction of 44% of uptake 
was observed when Methyl-β (Mβ)-CD was used while no efflux activity was observed. 
This may be particularly important when devising systems that can avoid efflux 
resistance mechanisms [90]. Together with size and architecture, the charge also 
determines preferential interactions within biological media, especially with cell 
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membranes. Although both positive and neutral dendrimers were distributed to all major 
organs with rapid clearance within 24 hours, deposition was slightly higher for the 
positively charged dendrimers at the tumor site [101]. Docosahexenoic acid-PAMAM 
dendrimers linked to doxorubicin by a hydrazone link were compared to free drug [102]. 
Since doxorubicin is linked to the dendrimer backbone, it cannot interact with its receptor 
due to steric hindrance. Therefore, as tumors are slightly more acidic than normal cells, 
release of doxorubicin was achieved by a pH-triggered mechanism by the hydrazone 
linker, resulting in 2-fold higher drug release in acidic conditions. Consequently, a higher 
area under the curve (AUC) was observed for the dendrimer (452 µg/mL versus 65 
µg/mL) that resulted in a higher growth inhibition and apoptotic induction in comparison 
to the free drug [102]. 
 
Paclitaxel, although not approved yet for melanoma therapy, has been extensively 
studied for this purpose. Paclitaxel promotes the polymerization of tubulin proteins, 
essential for microtubules stabilization during cell mytosis, inhibiting tumor growth [103]. 
Abraxane® is a nanoparticulate system with 130 nm in which paclitaxel is bounded to 
albumin protein (nab - nanoparticle albumin bound) and was first introduced and 
approved for breast cancer in 2005. The use of albumin, a natural human protein, 
prevents some additional toxicity and has shown to have reduced adverse effects 
compared to the traditional formulation (Cremophor®), which is commonly associated 
with hypersensitivity reactions and neuropathy [104]. There are various mechanisms by 
which nanoparticles can accumulate in the tumor but they can be divided into two major 
groups: (I) passive (i.e., enhanced permeation and retention (EPR), which is a series of 
phenomena related with enhanced blood circulation and leaky tumors) and (II) active 
targeting (e.g., folate, RGD or antibodies). Nab-paclitaxel achieves high concentrations 
within the tumor site both by EPR effect and receptor mediated targeting. Secreted 
protein acidic and rich in cysteine (SPARC) is highly secreted in malignant melanocytes 
and has been shown to be important in Abraxane® mechanism. The value of nab-
paclitaxel has recently been tested for its potential value in clinical trials for melanoma 
[105–107]. Nevertheless, there is always space for improvement in nanomedicine, where 
new opportunities constantly rise to explore other strategies. Nanoemulsions for dermal 
delivery of paclitaxel can work as localized therapy in deep skin layers for melanoma 
treatment in rats [108]. Another study compared liposomal paclitaxel carriers, showing 
that it increased the drug encapsulation up to 90%, overcoming a common problem in 
conventional lipid formulations, suppressed the tumor growth and the appearance of 
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metastasis in a dose-dependent rate, reducing the toxicity to normal tissues in mice 
[109]. 
 
Liposomes are extensively used for melanoma treatment, since they are low-toxicity 
systems and suitable for dermal application, decreasing adverse effects and increasing 
the local accumulation and action of the anti-tumor drug; also they allow prolonged 
systemic circulation when modified by PEGylation, for an effective treatment of 
metastastic melanoma [110]. Liposomes have been studied for encapsulation of 
common anti-tumor drugs in mono- or bi-therapy for synergistic effects, nucleic acids 
(gene therapy), improvement by addition of targeting moieties (e.g., folic acid, transferrin 
and monoclonal antibodies) [110]. Although liposomes are good platforms for topical 
drug delivery, most of the studies performed with them use invasive administration, such 
as i.v. injections, except when associated with other techniques like PDT [93].  
 
Cyclodextrins are cyclic oligomers of α-D-glucopyranose (or α-D-glucose) units linked by 
1,4-glicosidic bonds, produced by bacteria that degrade starch by an enzymatic process 
[111,112]. CD’s structure allows them to have a hydrophobic cavity and a hydrophilic 
outer surface, and the cavity’s dimension enables them to bind to several different 
compounds, generically called guest molecules, forming inclusion complexes [112,113]. 
Few studies were conducted with CDs for melanoma treatment. However, they revealed 
some interesting results that show CDs as promising carriers for this application. For 
example, betulinic acid, a pentacyclic lupane-type triterpene, widely found in a variety of 
plants and synthesized from betulin. As this compound is poorly soluble in aqueous 
medium, octakis-[6-deoxy-6-(2-sulfanyl ethanesulfonate)]-γCD was chosen as carrier 
and revealed that the complexation of this compound is potentially interesting for the 
treatment of melanoma, since it displays similar activity to free betulin (in cell lines) while 
allowing solubilization, and thus, making it possible for the compound to be administered 
in an aqueous (non-toxic) vehicle [114]. Another study reported a significant antitumor 
potential of mistletoe-derived triterpenes (which major component is oleanolic acid) with 
highest necrosis rates when animals received aqueous extract with CD-complexed 
triterpenes [115]. In fact, natural compounds and derivatives have been selected to be 
conjugated with CDs, as either carriers or active participants on the therapeutic effect for 
melanoma, promoting the cytotoxicity’s selectivity [116–120]. CDs can be administered 
by oral route [121], or topical administration, with successful results. A CD-surfactant 
carrier for topical application and delivery of two curcumin analogs showed remarkable 
cellular selectivity, within primary keratinocyte cells and human fibroblasts and high 
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apoptotic activity (five to nine-fold higher than untreated cells) [122]. Also, oleanolic acid 
and ursolic acid complexed with both HPβCD and HPγCD were applied topically in 
induced skin melanoma murine model [123]. By using the lipid layer-disrupting property 
of cyclodextrins, it appears that CDs can decrease the cell membrane constituent, 
syndecan-2, translocation to the lipid rafts, causing their disruption, which leads to 
melanoma cell migration inhibition [124]. 
 
Another recent and promising approach is the use of hyaluronidase coated plain silica 
nanoparticles. Recent experiments have found that subcutaneous (s.c.) injected 
nanoparticles in concomitance with a therapeutic agent (i.e., carboplatin) would stay 
longer and more attached to the skin tumor after administration. This facilitated 
attachment is due to the high molecular weight of the enzyme and the multiple 
interactions between nanoparticles and the hyaluronan present in cancer cells. The 
enzyme maintained its biological activity after immobilization into the particles. These 
systems were tested in human, non-metastatic melanoma cancer cell lines A375 
(overexpressing CD44 receptors for hyaluronic acid) and showed a higher decrease of 
the tumor size [125]. The use of bioactive compounds associated with nanocarriers is 
also increasing, such as tripterine (Tripterygium wilfordii) encapsulation in NLCs for 
topical treatment of skin cancer. Anionic NLCs allow a more controlled release over time, 
show better encapsulation efficiency, cumulative skin permeation, less cell inhibition and 
high cell uptake [12,17]. A recently synthesized derivative of the natural compound 
Royleanone (7α-acetoxyroyleanone) demonstrated cytotoxicity against melanoma cells; 
and also SK-MEL-1 human melanoma cells showed a special sensitivity to other 
derivatives of this compound, which is very promising for counteracting melanoma ’s 
MDR [126]. Curcumin was proven to be used for melanoma since it can have an 
immunotherapy action in melanoma treatment. It shows an immune responsive action 
by promoting the release of tumor pro-apoptotic cytokines that destroys human 
melanoma cell lines after 48 hours treatment [127]. However, curcumin also appears to 
inhibit the immune-mediated recognition of tumors by affecting the responsiveness to 
other anti-tumor factors (STAT1 and STAT5), so its use should be further studied [127]. 
It seems that curcumin acts by inhibiting cyclic nucleotide phosphodiesterases 1 (PDE1) 
in order to decrease melanoma cell proliferation and also may act by a preventive 
mechanism, via gene encoding the cell life cycle. Another study developed chitin 
nanogels for selective toxicity towards melanoma cells, with a safer behavior compared 
to the anti-tumor free drug (i.e., curcumin). This nanogel was applied via transdermal 
route mainly through both intercellular and transcellular pathways [13]. Curcumin has 
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also been encapsulated into nanoniosomes for dermal application as skin cancer 
prevention strategy [128].  Zhao et al. (2010) reported a high efficacy against melanoma 
in vivo through transdermal route by incorporation of realgar into nanosystems, with 
lower systemic toxicity levels [17]. Finally, corticosteroids, such as prednisolone 
phosphate, used in cancer treatment can be incorporated into liposomes for oral 
administration against melanoma. These liposomes, called long-circulating liposomes 
(LCLs), target tumor-associated macrophages (TAMs), which seem to control the tumor 
growth and angiogenesis, in immunogenic cancers [29].  
 
 
6. Other therapies: Gene and viral therapies 
 
Gene therapy involves a more complex approach in cancer treatment. It may be more 
promising for diagnosis than for treatment due to the genetic flexibility of tumor cells and 
the different molecular identities, including during metastasis. In this last case, we should 
develop a unique system that could reorient its structure, like a virus, according to the 
tumor adjustments. Some virus (e.g., vesicular stomatitis virus) demonstrated to 
selectively enter malignant melanoma cells working as a targeting machinery and vector 
for oncologic therapeutics, due to a defective barrier of the cancer cells for the virus. 
Besides the issues associated with unexpected viral reactions or consequences, the 
great variability of melanoma cancer cells can make them resistant to virus infection 
[129]. Yao et al. (2011) produced a carrier composed of PEI linked to βCD and 
conjugated with folate [130]. This carrier was studied mainly because of its ability to 
deliver interleukin IL-2 plasmid, after s.c. administration. The resulting polycomplex 
system had around 100 nm and was able to suppress tumor growth and extend animal 
survival. In addition, this polycomplex was able to stimulate a positive immune response, 
namely through CD4+ and 8+ LyT, and natural killer cells increase activation, 
proliferation and infiltration into the tumor, showing a constantly high level of IL-2 [130]. 
 
In alternative, the potential of small interfering RNA (siRNA) has also been studied. This 
approach reduced associated-therapy adverse effects, compared to classic agents and 
it is tumor specific. However, due to the lack of stability of the nucleic acids in the blood 
stream, nanoparticles work as a carrier to protect the molecule until it reaches the tumor 
site. Nanoparticulate systems may also interact synergistically with the agent to activate 
tumor cell death, avoiding all the biosafety issues related to the use of viral vectors [131]. 
When applied to the “suicide gene” approach, nanocarriers involve a therapy where a 
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gene is delivered to the tumor cells and transformed into an enzyme/protein by the cells’ 
machinery, which will convert a prodrug (e.g., ganciclovir) into a cytotoxic metabolite, 
reducing the cancer growth [132,133]. In fact, DNA molecules can be completely 
compacted into nanoparticles, to perform virus-like properties such as cell-targeted 
internalization and interaction with proteins. These multifunctional carriers – with less 
than 100 nm – can incorporate α-MSH at the surface in order to facilitate a receptor-
mediated endocytosis and increased DNA transfection more than three-fold over plain 
nanocarriers [134]. To finish, delivery of genetic materials through the skin has also been 
evaluated. Immunotherapy by transdermal administration of synthetic 
oligodeoxynucleotides with iontophoresis, preventing tumor growth and reaching deeper 
skin layers, like epidermis and dermis. However, in this case the nucleotides did not 
penetrate the tumor tissue, which results may be explained by non-specific antitumor 
immune response [135]. Topical delivery of siRNA using nanoliposomes targeted for 
BRAF (V600E) mutation and the signaling-related Akt3 protein (overexpressed in 
melanoma), combining low-frequency ultrasound – to increase cell permeability – has 
the potential to selectively decrease the expression of the mutant protein by 25-60%, 
inhibiting tumor growth [110]. Actually, it was possible to deliver siRNA specifically to 
melanoma cells, reducing the area injured; the authors also proposed this system as a 
potential way to decrease the melanoma development and invasion, like a nonsurgical 
approach, when applied to early melanocytic lesions. 
 
 
7. Future perspectives 
 
Development of effective medicines for introduction as final products in the market is a 
complex, expensive and slow process, hindered not straightforward application of the 
knowledge created mostly by the academia research to an industry scale [136]. The use 
of increasingly high number of materials, mostly natural biomolecules, improve the safety 
profile of medicines, but there is still an unknown response when conjugated with 
nanocarriers. In addition, there is a great controversy about how nanoparticles interact 
and move through the biological barriers, especially in the skin. Is this relationship 
dependent on size and system composition? The nanoparticles may interact with some 
mitochondrial and cell membranes and promote apoptosis events, and may play a role 
in internalization processes and affect the cells toxicity [137-138]. Are there also 
physicochemical factors determinants do nanoparticles entail? What kind of genotoxicity 
and molecular determinants? How does the exposure and biodistribution occur? And 
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finally, how can we regulate all these issues to guarantee its safety? In fact, in vitro 
results based on classical methods are difficult to evaluate [139–141]. Alternatives such 
as cell damage and microscopy tools are being explored. Answers and solutions should 
come into sight, as well as a way to deal with the high value in cost of this emerging 
adaptation, for both entrepreneurs and patients [142].    
 
 
8. Conclusion  
 
Melanoma is a complex cancer, with multiple stages and high genetic flexibility that 
compromise its diagnostic and treatment. More guidelines and cohort studies are needed 
to follow different populations and access relevant biomarkers, develop serious 
recommendations based on proven evidence and avoid lack of evidence, which 
promotes the variability. By reviewing several available guidelines [22, 143], it seems 
there are some particular differences especially in diagnose and disease follow-up and 
treatment. For example, Australian guidelines are stricter in terms of diagnostic and 
follow-up but for treatment there are more non-specific recommendations. This could 
help both assessment and innovation in melanoma diagnostics and therapies. 
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BACKGROUND 
 
1. As a natural biological barrier, the skin limits permeation to a few numbers of 
drugs with singular characteristics (e.g., low molecular weight, moderate lipophilicity and 
great potency) [1,2]. To improve skin permeation, combination of physical methods (i.e., 
iontophoresis, electroporation) and chemical enhancers (i.e., surfactants and organic 
solvents) are selected for development of conventional formulations; however, some of 
those strategies usually cause adverse side effects, such as: disruption of the stratum 
corneum (skin outer barrier), alteration of the skin’s physiological pH, inflammatory and 
immunologic reactions and bacterial infections, which reduce the treatment efficacy [3]. 
 
2. Skin keratinocytes regulate growth and differentiation of melanocytes through 
interaction of multiple receptors and ligand-mediated activation [4]. One of these 
receptors is the melanocortin-1 receptor (MC1R), which mutation is related with skin 
carcinoma [4,5]. MC1R is activated by alpha-melanocyte stimulating hormone (α-MSH), 
which is up-regulated in melanoma tissues than in other cells, such as normal 
melanocytes, keratinocytes, activated macrophages and immature dendritic cells [6]. 
This natural ligand molecule is mainly expressed intracellularly, but it is also present on 
the cell surface, showing a protective and metastasis-retard action in melanoma cells 
[4,6,7].  
 
3. Epidermal Growth Factor Receptor (EGFR), a cell-surface receptor belonging to 
ErbB family of tyrosine kinases, is overexpressed in several cancers, such as melanoma 
[8,9], being responsible for melanoma growth and metastasis [10]. Epidermal Growth 
Factor (EGF) is the natural ligand peptide, which appears to act directly on the 
endothelial cells, promoting angiogenesis, such as on development of melanoma lymph 
node metastases, where it is up-regulated [10].  
 
4. Emerging therapies for melanoma are currently focused on targeted 
chemotherapy or phototherapy, achieved by functionalizing nanoparticles with specific 
tumor targeting molecules [11,12]. Hybrid nanoparticles are developed for mitigating 
limitations and obtain synergistic advantages by a broad range of chemically modified 
polymeric-based nanosystems [13]. Self-assembled hybrid nanoparticles may favor of 
improved physical and chemical drug stability, versatile drug loading and release profiles, 
as well as an increased and highly specific efficiency [14,15].  
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HYPOTHESIS 
 
1. Considering multiple applications of targeted drug delivery systems, hybrid lipid-
polymer nanoparticles were developed for application in melanoma chemotherapy. 
Moreover, those nanoparticles were conjugated with a specific ligand, such as α-
melanocyte stimulating hormone (α-MSH), in order to efficiently deliver an anti-tumor 
drug to the cancer site, with minimal toxicity to healthy tissues. On the other hand, 
both new and model anti-tumor agents, derived from plants, were assessed. 
 
2. As an alternative to chemotherapy, hybrid polymeric-gold nanoparticles were 
developed for application in melanoma photothermal therapy. Gold nanoparticles 
were produced by a “green” reduction method, using phytochemicals. In addition, 
those nanoparticles were conjugated with a specific ligand, such as Epidermal 
Growth Factor (EGF), in order to efficiently accumulate at the tumor site, for further 
laser irradiation, with minimal toxicity to healthy tissues. Both laser and gold 
nanoparticles showed light absorbing properties at near infrared (NIR) region, in 
order to minimize the damage of surrounding healthy tissue.  
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OBJECTIVES 
 
Regarding what has been previously presented, we propose the investigation of the 
application of hybrid lipid-polymer nanoparticles and hybrid polymer-gold nanoparticles 
for targeted chemotherapy and phototherapy of melanoma, respectively. To achieve 
these objectives, we have pursuit the following steps:  
 
1. Development of hybrid lipid-polymer nanoparticles for targeted 
transdermal drug delivery 
 
In this part, we have designed hybrid nanoparticles, with a core structure made of 
polyester polymer and long-chain fatty acids (stearic acid), and coated with another fatty 
acid (oleic acid), described as a permeation enhancer. Betamethasone-21-acetate was 
firstly used as a hydrophobic model drug for studying the nanoparticles release profile 
and in vitro and in vivo skin permeation.  
 
The main results regarding this milestone were reported in Article II: 
Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-
inflammatory treatment. International Journal of Pharmaceutics. (2015). 493(1-2):271-
284. doi: 10.1016/j.ijpharm.2015.07.044.  
 
 
2. Development of hybrid polymer-gold nanoparticles for targeted 
photothermal therapy 
 
In this step, we have designed hybrid nanoparticles, made of a gold core and polymeric 
coating, composed by a polysaccharide (hyaluronic acid) and a fatty acid (oleic acid). 
Bio-production of gold nanoparticles with phytochemicals obtained from an aqueous 
extract of Plectranthus sp. were assessed. Moreover, lysozyme was associated to the 
nanoparticles surface as a model protein of targeting peptides, and its photostability 
before and after conjugation was evaluated. 
 
The main results regarding this milestone were reported in Article III and IV and in 
Supplementary Information: 
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Lysozyme photochemistry as a function of temperature. The protective effect of 
nanoparticles on lysozyme photostability. PLoS One. (2015). 10(12):e0144454. doi: 
10.1371/journal.pone.0144454.  
 
Bio-production of gold nanoparticles for photothermal therapy. Therapeutic Delivery 
(2016). 7(5):287-304. doi: 10.4155/tde-2015-0011. 
 
Request of national patent nº 20151000093093 (Portugal). Nanossistema de ouro com 
revestimento biopolimérico e gama de absorção no infravermelho próximo e método 
para a sua preparação. 2015.  
 
 
3. Physico-chemical characterization and in vitro bio-characterization of 
targeted hybrid lipid-polymer nanoparticles for melanoma chemotherapy 
 
In this chapter, we have improved hybrid nanoparticles for targeted drug delivery by 
combining hyaluronic and oleic acids, as the coating material, and α-melanocyte 
stimulating hormone (α-MSH), as the specific surface ligand. Parvifloron D and paclitaxel 
were selected as the anti-tumor drugs. Both drugs are isolated from plant extracts. 
Nanosystems were characterized in terms of physico-chemical features, release profile, 
in vitro permeation and cytotoxicity. 
 
The main results regarding this milestone were reported in Article V: 
Functionalized diterpene Parvifloron D loaded hybrid nanoparticles for target delivery in 
melanoma therapy. Therapeutic Delivery (2016).  7(8), 521–544. doi: 10.4155/tde-2016-
0027 
 
4. Physico-chemical characterization and in vitro bio-characterization of 
targeted hybrid polymer-gold nanoparticles for melanoma photothermal 
therapy 
 
In this chapter, we have associated Epidermal Growth Factor (EGF) onto the surface of 
hybrid polymeric-gold nanoparticles for targeted photothermal therapy. EGF was 
assessed for its photostability, before and after conjugation with nanoparticles. Resultant 
nanosystems were characterized in terms of physico-chemical properties, in vitro 
cytotoxicity and receptor-mediated internalization. 
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The main results regarding this milestone were reported in Annex I: 
EGF functionalized polymer-coated gold nanoparticles promote EGF photostability and 
EGFR internalization for photothermal therapy. (2016). PLoS One (submitted, under 
review).  
 
 
5. In vivo efficacy studies  
 
In this chapter, in vivo efficacy studies were conducted on SCID mice used as xenograft 
models for human melanoma (A375 cell line). Both targeted chemotherapy and 
phototherapy were evaluated independently on mice with cutaneous melanoma. Tumor 
volume after treatment and histological analysis were assessed.  
 
The main results regarding this milestone were reported in Annex II: 
In vivo efficiency and safety studies of photothermal therapy for human cutaneous 
melanoma (Publication pending).  
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Supporting Materials 
 
Table S1. SEM images of non-coated nanoparticles (i.e. bare core nanoparticles) and 
HAOA-coated nanoparticles, as an aqueous suspension, exposed to 4 ºC, 25 ºC and 37 
ºC, for over 12 months. Scale bars range from 500 nm to 10 µm. 
 
Time 
(months) 
Non-coated nanoparticles HAOA-coated 
nanoparticles 
T = 4 ºC ± 2 ºC 
1 
  
3 
  
6 
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9 
  
12 
  
 
T = 25 ºC ± 2 ºC 
1 
  
3 
  
6 
  
9 x x 
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12 x x 
 
T = 37 ºC ± 2 ºC 
1 
  
3 
  
6 x 
 
9 x 
 
12 x 
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Figure S1. UV-Visible spectra (from 200 nm until 1000 nm) of non-coated nanoparticles 
and HAOA-coated nanoparticles, as an aqueous suspension, exposed to 4ºC (total time: 
12 months), 25ºC (total time: 6 months) and 37ºC (total time: 6-12 months), for over 12 
months. 
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Figure S2. Nanoparticle physicochemical parameters, as aqueous suspensions: (A) 
size, (B) polydispersity index, PI, (C) pH and (D) zeta potential, ZP, of empty non-coated 
nanoparticles (i.e., bare core nanoparticles), as dashed line, and HAOA-coated 
nanoparticles, as continuous line, over 12 months (360 days) for nanoparticles stored at 
4 ± 2ºC (), 6 months (180 days) for nanoparticles stored at 25 ± 1ºC () and 3-12 
months (90-360 days) for nanoparticles stored at 37 ± 1ºC ().Results are expressed as 
mean of measurements of three independent nanoparticles batches ± SD (n=3). 
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Table S2. FT-IR spectra main peaks and correspondent functional groups identified for 
all tested samples as raw components. For physical mixtures and nanoparticles, the 
peaks are identified based on the functional groups of the raw components 
(wavenumbers: 4000-400 cm-1). 
Samples 
Peaks and correspondent functional 
groups 
Raw Materials 
Poly-ε-caprolactone 
IR (KBr) ν 1730 cm-1 (C=O stret.), 1296 
cm-1 (C-O, C-C stret. in crystalline 
phase), 1106 cm-1 (C-O stret.), 1046 cm-1 
(C-C stret.) and 732 cm-1 (CH2 rock.). 
Pluronic® F-127 
IR (KBr) ν 2887 cm-1 (C-H stret.), 1467 
cm-1 (O-H in-plane), 1343 cm-1 (O-H 
bend.), 1281 cm-1 (C-O stretch.), 1113 
cm-1 (C-O-C stret.), 964 cm-1 and 842 
cm-1. 
Stearic Acid 
IR (KBr) ν 2915 cm-1, 2849 cm-1, 2655 
cm-1, 1702 cm-1,1464 cm-1 (O-H in-
plane),1298 cm-1 (C=C),~ 900 cm-1 (O-H 
out-plane) and 719 cm-1 (C=C rock.). 
Oleic Acid 
IR (KBr) ν 2926 cm-1 (CH2 strech.),2856 
cm-1 (CH2 strech.), 1711 cm-1 (C=O 
stretch.), 1467 cm-1 (O-H in-plane), 1287 
cm-1 (C-O stretch.),1245 cm-1,~ 900 cm-1 
(O-H out-plane) and 617 cm-1 
Hyaluronic Acid 
IR (KBr) ν 3412 cm-1 (NH stretch.), 2908 
cm-1, 1652 cm-1 (NH2 bend.), 1618 cm-1 
(amine I), 1558 cm-1 (amine II), 1418 
cm1, 1370 cm-1, 1322 cm-1 (amine III), 
1314 cm-1, 1233 cm-1 and 1035 cm-1. 
PvD  
IR (KBr) ν 3328 cm-1, 2959 cm-1, 2923 
cm-1, 2347 cm-1, 1668 cm-1, 1609 cm-1, 
1591 cm-1, 1520 cm-1, 1443 cm-1, 1351 
cm-1, 1314 cm-1, 1292 cm-1 (C-O, C-C 
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stret.), 1163 cm-1, 1119 cm-1, 1049 cm-1, 
846 cm-1 and 772 cm-1. 
Physical mixtures (1:1 w/w) 
All components (except drug and 
peptide) 
IR (KBr) ν 2917 cm-1 (CH2 strech.), 2856 
cm-1(CH2 strech.), 1705 cm-1 (C=O 
stretch.), 1465 cm-1 (O-H in-plane), 1406 
cm-1, 1359 cm-1, 1340 cm-1, 1292 cm-1 
(C-O stretch.), 1056 cm-1, 957 cm-1 (O-H 
out-plane) and 717 cm-1. 
Hyaluronic and oleic acids (1:1, w/w) 
IR (KBr) ν 3008 cm-1, 2924 cm-1 (CH2 
strech.), 2853 cm-1 (CH2 strech.), 1709 
cm-1 (C=O stretch.), 1650 cm-1 (NH2 
bend.), 1408 cm-1, 1336 cm-1 (Amine III), 
1075 cm-1, 912 cm-1 (O-H out-plane) and 
717 cm-1. 
HAOA polymer 
IR (KBr) ν 3432 cm-1 (NH stretch.), 2924 
cm-1, 2849 cm-1 (CH2 strech.), 2362 cm-1, 
2325 cm-1, 1738 cm-1 (C=O stret.), 1701 
cm-1 (C=O stret.), 1561 cm-1, 1462 cm-1, 
1403 cm-1, 1384 cm-1 (amine III), 1288 
cm-1, 1252 cm-1, 1089 cm-1, 1034 cm-1, 
931 cm-1 (O-H out-plane), 853 cm-1 and 
721 cm-1 
Empty HAOA-coated nanoparticles + 
free PvD (1:1, w/w) 
IR (KBr) ν 2946 cm-1, 2863 cm-1, 2360 
cm-1, 1727 cm-1 (C=O stret.), 1668 cm-1 
(NH2 bend.), 1606 cm-1, 1591 cm-1, 1521 
cm-1, 1365 cm-1 (O-H bend.), 1241 cm-1, 
1049 cm-1, 960 cm-1, 842 cm-1 and 769 
cm-1. 
Nanoparticles 
Empty non-coated nanoparticles 
IR (KBr) ν 2947 cm-1, 2869 cm-1, 1727 
cm-1 (C=O stret.), 1559 cm-1, 1472 cm-1, 
1419 cm-1, 1294 cm-1, 1241 cm-1, 1177 
cm-1, 1110 cm-1, 1049 cm-1, 962 cm-1 and 
734 cm-1. 
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Empty HAOA-coated nanoparticles 
IR (KBr) ν 2912 cm-1, 2860 cm-1, 1749 
cm-1 (C=O stret.), 1715 cm-1, 1652 cm-1 
(NH2 bend.), 1558 cm-1, 1418 cm-1, 1368 
cm-1, 1234 cm-1, 1048 cm-1, 961 cm-1 and 
933 cm-1. 
PvD-loaded HAOA-coated 
nanoparticles 
IR (KBr) ν 2945 cm-1, 2868 cm-1, 2360 
cm-1, 2342 cm-1, 1728 cm-1 (C=O stret.), 
~ 1652 cm-1 (NH2 bend.), 1631 cm-1, 
1554 cm-1, 1419 cm-1, 1367 cm-1 (O-H 
bend.), 1242 cm-1, 1049 cm-1, 841 cm-1 
and 733 cm-1. 
α-MSH-conjugated HAOA-coated 
nanoparticles 
IR (KBr) ν 3400 cm-1, 2929 cm-1, 2862 
cm-1, 1730 cm-1 (C=O stret.), 1645 cm-1, 
1364 cm-1 (O-H bend.), 1241 cm-1, 1050 
cm-1, 961 cm-1 and 933 cm-1. 
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Table S3. Description of the main NMR signals for 1H-NMR and 13C-NMR (300 MHz, 
D2O, DMSO-d6 and CDCl3) of the following samples: empty non-coated nanoparticles 
(i.e., bare core), empty HAOA-coated nanoparticles and PvD-loaded HAOA-coated 
nanoparticles. 
Sample 
Empty non-coated 
nanoparticles 
δ 13C (ppm) δ 1H (ppm) 
CDCl3 
Stearic acid, (CH3; CH2) 28.33 0.064 (m); 1.61(m) 
Poly-ε-caprolactone 
(COCH2; CH2COO; CH2O) 
24.55; 25.50; 
34.10; 64.14; 
173.52 
1.64 (m); 2.28 (t); 
4.03 (t) 
Pluronic® F-127 (C2H4) 70.54 3.64 (s) 
DMSO-d6 
SA (CH3) - 0.059 (t); 1.21(s) 
Poly- ε -caprolactone 
(COCH2, CH2COO, CH2O) 
- 
1.50 (m); 2.25 (t); 
3.96 (t)  
Pluronic® F-127 (C2H4) - 1.01 (d); 3.49 (m) 
D2O 
Pluronic® F-127 
(OCH2CHCH3O) 
69.47; 105.0 1.01(d); 3.54 (s) 
Sample 
Empty HAOA-coated 
nanoparticles 
δ 13C (ppm) δ 1H (ppm) 
CDCl3 
Stearic and oleic acids, 
CH3 
30.96 
0.87 (m); 1.24 (s); 
3.38 (m); 5.34 (t) 
Poly- ε -caprolactone, 
(CH2)3, COCH2, CH2COO, 
CH2O 
24.55; 25.51; 
28.31; 29.27; 
34.08; 64.12; 
173.52 
1.39 (m); 1.64 (m); 
2.30 (t); 4.05 (t) 
Hyaluronic acid - 
1.99 (t); 3.54 (m); 
4.22 (t) 
Pluronic F-127® 70.52 3.67 (m) 
DMSO-d6 
Stearic and oleic acids, 
CH3 
28.57; 54.68; 
69.28 
0.83 (d); 1.22 (d); 
1.28 (s); 2.25 (t); 
5.30 (t) 
Poly- ε-caprolactone 
(CH2)3, COCH2, CH2COO, 
CH2O) 
23.58; 26.05; 
33.69 
1.53 (m); 2.26 (s); 
3.96 (t) 
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Hyaluronic acid - 
1.95 (d); 2.11 (t); 
3.54 (s) 
Pluronic® F-127 - 
1.02 (d); 2.71 (s); 
3.48 (s); 
D2O 
Pluronic® F-127 
(OCH2CHCH3O) 
70.21 1.13 (m); 3.54 (s) 
Hyaluronic acid (anomeric 
H) 
- 4.60 (s); 4.70 (s) 
Sample 
PvD-loaded HAOA-
coated nanoparticles 
δ 13C (ppm) δ 1H (ppm) 
CDCl3 
Stearic and Oleic acid 
(CH3; CH2) 
29.68 
0.87 (m); 1.25 (s); 
5.34 (t) 
Poly- ε-caprolactone 
(COCH2; CH2COO; CH2O) 
24.55; 25.51; 
28.33; 34.14; 
64.14; 173.50 
1.38 (m); 1.70 (m); 
2.30 (t); 4.07 (t) 
Pluronic® F-127 (C2H4) 63.26; 70.51 3.64 (s) 
Hyaluronic acid - 
2.02 (d); 3.65 (m); 
4.21 (t) 
PvD 
22.66; 69.06; 
129.70 
1.12 (m); 1.35 (d); 
3.71 (d) 
DMSO-d6 
Stearic and Oleic acid 
(CH3; CH2) 
 
0.83 (d); 2.25 (t); 
5.31 (t) 
Poly- ε-caprolactone 
(COCH2; CH2COO; CH2O) 
22.50; 24.89; 
63.87 
1.48 (m); 3.94 (t) 
Pluronic® F-127 (C2H4) 70.872 1.01 (d); 3.48 (s) 
Hyaluronic acid - 1.95 (d) 
PvD 130.05 1.22 (m); 3.28 (t) 
D2O 
Pluronic® F-127 
(OCH2CHCH3O) 
29.26; 69.47; 
75.04; 129.62; 
173.15 
0.96 (m); 1.13 (m)  
Hyaluronic acid (anomeric 
H) 
- 
3.41 (m); 4.59 (s); 
4.70 (s) 
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Table S4. Elemental Composition of C 1s and O 1s, for non-coated nanoparticles and 
HAOA-coated nanoparticles, regarding position (binding energy, counts eV), full width at 
half-maximum intensity (FWHM) (counts, eV) and area (%) of the X-PS spectra.  
Sample Element 
Binding 
energy (counts 
eV) 
FWHM 
Intensity 
(counts eV) 
Area (%) 
Non-coated 
nanoparticles 
C 1s 287.6 3.41 71.75 
O 1s 534.6 2.53 28.25 
HAOA-coated 
nanoparticles 
C 1s 286.6 2.50 86.39 
O 1s 534.6 2.85 13.61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annex I 
Ligand-functionalized nanoparticles for targeted therapy of melanoma in situ 
177 
 
Annex I 
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Abstract 
 
Background: UVB induced photochemistry of tryptophan and tyrosine residues in 
proteins leads to the formation of photoproducts, such as kynurenine, N–
formylkynurenine and dityrosine and to the disruption of disulphide bridges. Epidermal 
Growth Factor (EGF) is a small peptide with key medical relevance and a good model 
protein for photochemical studies. Methods: This study reports the behaviour of EGF 
when exposed to UVB light (295 nm), temperature and quenchers, such as polymer-
coated gold nanoparticles. Results: Gold nanoparticles (100 – 200 nm) were produced 
by reduction with an aqueous plant extract and coated with oleic acid and hyaluronic 
acid, showing a plasmon absorption band located within the near-infrared range (650-
900 nm), optimal for photothermal therapy applications. Conjugation of EGF onto the 
nanoparticles was verified by fluorescence spectroscopy, confocal fluorescence 
microscopy and circular dichroism. Cytotoxicity studies of EGF-conjugated nanoparticles 
carried out in normal-like human keratinocytes (HaCaT) showed small decreases in cell 
viability (0-25%), concentration dependent. EGF-conjugated nanoparticles were able to 
activate and induce the internalization of EGFR in human lung carcinoma cells (A549 
cells) overexpressing EGFR tagged with GFP. Conclusions: EGF photochemistry is 
observed to be both temperature and light power dependent and conjugation of EGF 
with polymeric-coated gold nanoparticles reduced or even avoided the formation of 
photoproducts, such as, kynurenine and N–formylkynurenine.  
 
Keywords: Epidermal Growth Factor; Epidermal Growth Factor Receptor; UVB light; 
Photochemistry; Gold nanoparticles; Receptor activation and internalization.  
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1. Introduction   
 
UV induced photo-oxidation causes protein conformational changes upon excitation of 
the aromatic residues, i.e., tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe). 
Three main photoproducts are kynurenine (Kyn, a photoproduct of Trp), N–
formylkynurenine (NFK, a photoproduct of Trp) and dityrosine (DT, a photoproduct of 
Tyr) [1–5]. Since fluorescence excitation and emission spectra of NFK, Kyn and DT differ 
from the fluorescence spectra of Trp and Tyr, formation of photoproducts can be 
monitored by fluorescence spectroscopy [1]. Furthermore, UV excitation of the side 
chains of aromatic residues induces the disruption of disulphide (SS) bonds mediated by 
an electron transfer process, leading to the formation of a transient disulphide electron 
adduct [4]. SS bonds are known to be excellent quenchers of protein fluorescence and 
their reduction leads to changes in the fluorescence quantum yield of proteins [3]. 
 
The effect of UV light on the structure and function of key medically relevant proteins, 
such as Epidermal Growth Factor Receptor (EGFR) [6], insulin [1] and plasminogen [2] 
has been reported. Correia et al. (2014) have shown that 280 nm excitation of EGFR 
hinders EGF binding to this specific receptor, which most likely explains why such 
wavelengths can halt signalling pathways (e.g., AKT and ERK1/2 pathways) responsible 
for cancer cells’ proliferation and differentiation [6]. EGFR is involved in cell proliferation, 
migration, in cancer growth and invasion [6,7]. EGFR is a cell surface receptor that 
belongs to the ErbB family of receptors and to the subfamily of receptor tyrosine kinases 
[8].  EGFR is upregulated in several cancers, such as melanoma [8], and its 
overexpression is correlated with the appearance of melanoma metastases [9]. EGF 
shows high affinity to EGFR, promoting its dimerization and internalization by 
endocytosis, which then activates the intracellular tyrosine kinase domain and a 
downstream signaling pathway necessary for cell growth. 
 
Bio-functionalization of nanoparticles with EGF has been applied to specific targeting 
cancer cells, which overexpress EGFR and, therefore, with ample interest for cancer 
treatment. EGF offers many advantages for this type of pharmaceutical application: 1) 
EGF is smaller (53 amino acids; MW 6 kDa) than antibodies or other EGFR specific 
ligands used for the same purpose; 2) unlike EGF, antibodies can trigger severe immune 
response leading to cytotoxicity [10,11]; 3) EGF has three SS bonds, three Trp and five 
Tyr and hydrophobic residues, all suitable for interactions with nanocarriers [12,13]; and 
4) EGF is stable at physiological conditions and neutral pH since its pI value is around 
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4.55, conferring the peptide a negative charge at pH > 7 [14]. The use of oleic acid (OA) 
and polymers like hyaluronic acid (HA) can further promote the interaction and 
entrapment of EGF onto gold nanoparticles, independently of the pI and pH of the 
solution, as previously reported [15]. Fourier Transform Infrared (FT-IR) studies also 
showed that EGF presents a thermal unfolding at pH 7.2 that starts at 40ºC, with the 
transition midpoint at 55.5 ºC and complete denaturation is observed above 76ºC [16]. 
Another study evaluated the application of EGF for skin patches, showing the resistance 
of this peptide to temperature (Tm ~ 79 ºC) [17].  
 
It is our aim to use EGF-conjugated HAOA-coated gold nanoparticles with plasmon 
absorption band located in the near-infrared (NIR) range (i.e., 650-900 nm), for 
photothermal therapy and local hyperthermia, without damage to the surrounding tissues 
[18]. This study describes the behaviour of EGF when exposed to temperature, UVB light 
(295 nm) and quenchers, such as gold nanoparticles coated by hyaluronic and oleic 
acids (HAOA). The presence of quenchers shortens the fluorescence lifetimes and may 
confer protection against photochemistry. HA is described to be an excellent 
fluorescence quencher [19] and to give structural stability to small proteins [20]. OA is 
also described as a good protein fluorescence quencher [21]. The present study reports 
the time dependent effect of continuous 295 nm excitation of free EGF on the peptide’s 
fluorescence emission intensity, as a function of irradiance level (power/unit area) and 
temperature. Trp was selected as an intrinsic molecular probe and SYPRO® Orange was 
used as an extrinsic molecular probe in order to monitor protein conformational changes 
[22]. The formation of photoproducts, NKF, Kyn and DT, has been monitored. Moreover, 
the expected protective effect provided by HAOA-coated gold nanoparticles against 295 
nm-induced photochemistry on EGF was investigated by fluorescence spectroscopy. 
Kinetics of the observed photochemical processes were analyzed and compared for free 
EGF and EGF conjugated to HAOA-coated gold nanoparticles. Structures of free EGF 
and EGF-conjugated HAOA-coated gold nanoparticles were monitored using circular 
dichroism spectroscopy. Binding of EGF and EGF-conjugated HAOA-coated gold 
nanoparticles to EGFR, present on the cell membrane of A549 human lung carcinoma 
cells, was monitored using confocal fluorescence microscopy. Cytotoxicity assays (MTT) 
were carried out in human immortalized keratinocytes, HaCaT cell line, in order to assess 
the toxicity of the nanoparticles on non-cancerous cells.  
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2. Materials and methods  
 
2.1 Materials 
Gold (III) chloride trihydrate (HAuCl4) (PubChem ID: 24895143; Product number: 
G4022), L-ascorbic acid (L-AA) (PubChem ID: 24891246; Product number: A7506), 
silver nitrate (AgNO3) (PubChem ID: 24852543; Product number: S0139), hyaluronic 
acid (HA) sodium salt from Streptococcus equi (MW 7,000-250,000 g.mol-1) (PubChem 
ID: 24878223; Product number: 53747), oleic acid (OA) (MW 282.46 g.mol-1) (PubChem 
ID: 24886786; Product number: 75090) were all supplied by Sigma-Aldrich (Steinheim, 
Germany). Recombinant Human Epidermal Growth Factor (EGF) (PubChem ID: 
62253638), Alexa Fluor® 647 and SYPRO® Orange Protein Gel Stain (5,000X 
Concentrate in DMSO) were purchased from Life Technologies as molecular probes for 
confocal microscopy and protein conformational studies. Primary mouse monoclonal 
antibody anti-EGFR neutralizer antibody LA1 was obtained from Millipore (05-101). The 
water used for buffer preparation was purified through a Millipore system. Thiazolyl Blue 
Tetrazolium Bromide (MTT), Fetal Bovine Serum (FBS), puromycin and 
penicillin/streptomycin were supplied by Sigma-Aldrich (Steinheim, Germany), as of cell 
culture grade. Dulbecco's Modified Eagle's medium (DMEM) was supplied by Biowest 
(Nuaillé, France) and DMSO was supplied by Merck (Darmstadt, Germany). 
 
2.2 Preparation of EGF stock solution and EGF-conjugated gold nanoparticles 
A 2.5 µM (16.5 µg/mL) stock solution of EGF was prepared in 2 mM Phosphate Buffer 
Saline (PBS) at pH 7.4. In order to prepare EGF-conjugated HAOA-coated gold 
nanoparticles, the EGF stock solution at 2.5 µM was mixed with the gold nanoparticles 
solution (0.22 mM) and hyaluronic acid-oleic acid (HAOA) solution (1 mg/mL), at a 1:1 
(v/v) ratio. The reaction mixture was kept for 30 min at room temperature and, then, left 
overnight at 4ºC protected from the light. Gold nanoparticles were produced based on 
the addition of an aqueous extract of Plectranthus saccatus (10 mg/ mL) as the main 
reducing and capping agent. The aqueous plant extract was used in alternative to cetyl 
trimethylammonium bromide (CTAB), and prepared according to the procedure 
described by Rijo et al. (2014), using a microwave method [23]. The nanoparticles 
suspension was centrifuged twice at 500 x g for 20 min in a FV2400 Microspin (BioSan, 
Riga, Latvia) to remove unbound peptides. The pellet was re-suspended in PBS buffer 
(pH 7.4). EGF stock solution was stored at -20 ºC until further use.  
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2.3 EGF structure analysis and gold nanoparticles structure design 
Crystallographic data used for the display of the 3D protein structure was extracted from 
1JL9.pdb (3D structure of EGF, chain B), using Discovery Studio 4.1 (Accelrys Software, 
San Diego, CA, USA). Distances between protein residues were obtained by using the 
monitor tool in the program. Adobe Illustrator CS5 (Adobe Systems Software Ireland 
Ltd.) was used in order to graphically display the EGF-conjugated HAOA-coated gold 
nanoparticles.  
 
2.4 Steady-state fluorescence spectroscopy studies 
Steady-state fluorescence emission spectra were collected upon excitation of the Trp 
pool of the protein at 295 nm. Excitation spectra were acquired with emission wavelength 
at 330 nm. All measurements were conducted on a fluorescence RTC 2000 spectrometer 
(Photon Technology International, Canada, Inc.347 Consortium Court London, Ontario 
N6E 2S8) with a T-configuration, using a 75-W Xenon arc lamp coupled to a 
monochromator. Samples were analyzed in quartz high precision cell with 10 cm x 2 cm 
of light path (Hellma Analytics) and gently shaken before each measurement. All slits 
were set to 5 mm.  
 
2.4.1 Continuous 295 nm illumination of EGF  
2.4.1.1 Temperature effect on EGF photochemistry 
Continuous 295 nm illumination of EGF (fresh sample, 2.5 µM) was carried out for 2 hours 
and the protein’s fluorescence emission intensity at 330 nm was monitored at five different 
temperatures: 10 ºC, 15 ºC, 20 ºC, 25 ºC and 30 ºC. Excitation slit was set at 0.8 mm, 
with an equivalent lamp power of 1.67 µW. Fresh samples were used for each experiment. 
Emission and excitation intensity spectra were corrected in real-time for oscillations in the 
emission intensity of the excitation lamp. The Arrhenius plot for free EGF was also 
represented and all parameters calculated, as explained further in the “Data analysis” 
section. 
 
2.4.1.2 Light power effect on EGF photochemistry 
Continuous 295 nm illumination of EGF (fresh sample, 2.5 µM) was carried out for 2 hours 
and the peptide’s fluorescence emission intensity at 330 nm was monitored using different 
excitation slit openings: 0.1 mm, 0.5 mm, 0.8 mm, 1.2 mm and 2.0 mm corresponding to 
0.12 µW, 0.30 µW, 1.67 µW, 2.34 µW and 4.40 µW, respectively. Fluorescence excitation 
(em. fixed at 330 nm) and emission (exc. fixed at 295 nm) spectra of EGF were acquired 
before and after each EGF illumination using different excitation slit openings. The 
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excitation slit size versus excitation power was determined by measuring the power level 
at the cuvette location with a power meter (Ophir Photonics StarLite Meter ASSY ROHS, 
P/N7Z01565, Jerusalem, Israel) and a power head (Ophir Photonics, 30A-BB-18 ROHS, 
P/N7Z02692, Jerusalem, Israel) upon varying the excitation slit size, as previously 
reported for lysozyme [24]. The temperature of the solution was kept at 20 °C using a 
Peltier element at the cuvette holder location. A fresh sample was used for each 
illumination session.  
 
2.4.1.3 SYPRO® Orange: probing EGF conformation changes induced by 295 nm and 
temperature  
SYPRO® Orange is used as a molecular probe in order to monitor protein conformational 
changes since its fluorescence is greatly enhanced upon contact with hydrophobic 
environments [25]. A 2 µL aliquot (dilution 1:1000) of SYPRO® Orange stock solution 
(5,000X Concentrate in DMSO) was added to a cuvette containing a fresh sample of EGF 
(2.5 µM, 0.2 mL) prior to the 295 nm continuous illumination experiment. The sample was 
gently shaken to mix both solutions. Fluorescence emission of SYPRO® Orange at 580 
nm was monitored upon continuous illumination at 470 nm for 2 hours, at each of the 
above mentioned temperatures, i.e., 10 ºC, 15 ºC, 20 ºC, 25 ºC and 30 ºC. Fluorescence 
intensity changes were quantified. In addition, the fluorescence emission of SYPRO® 
Orange at 580 nm was monitored upon continuous illumination at 470 nm for 2 hours, at 
each of the above mentioned power levels, i.e., 0.12 µW, 0.30 µW, 1.67 µW, 2.34 µW 
and 4.40 µW (corresponding to 0.1 mm, 0.5 mm, 0.8 mm, 1.2 mm and 2.0 mm slits, 
respectively). Fluorescence spectral changes were quantified. 
 
2.4.1.4 Photoproducts of tryptophan and tyrosine  
Fluorescence excitation and emission spectra of the Trp and Tyr photoproducts (e.g., 
NFK, Kyn and DT) were monitored. Excitation and emission fluorescence spectra of the 
photoproducts differ from the ones of Trp and Tyr: NFK and Kyn are excited at 320 nm 
and 360 nm and show a maximum emission between 400-440 nm and between 434-480 
nm, respectively [26–28]. Therefore, EGF fluorescence intensity changes and spectral 
shifts were quantified, before and after the illumination of EGF at 295 nm, at different 
temperatures and different light power slit openings. 
 
2.4.2 Photochemistry of EGF conjugated with HAOA-coated gold nanoparticles 
The effect of continuous 295 nm excitation of EGF has been investigated for EGF 
conjugated to gold nanoparticles covered by natural polymers, such as hyaluronic acid 
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(HA) and oleic acid (OA). Results were compared with data obtained with free EGF. Four 
samples were continuously illuminated with 295 nm light for 2 hours at 20 ºC and their 
fluorescence emission intensity at 330 nm has been monitored: a) free EGF, b) EGF-
conjugated HAOA-coated nanoparticles, c) plain non-coated gold nanoparticles and d) 
HAOA-coated gold nanoparticles. Based on previous studies [24], excitation slit was set 
to 2.0 mm, with an equivalent power of 4.40 µW at the entrance of the excitation chamber. 
Conjugation of EGF onto the HAOA-coated gold nanoparticles has been confirmed using 
steady state fluorescence spectroscopy. Fluorescence excitation (em. fixed at 330 nm) 
and emission (exc. fixed at 295 nm) spectra of non-conjugated EGF, of the supernatant 
after centrifugation of the solution containing conjugated and non-conjugated EGF, and 
of conjugated EGF onto HAOA-coated gold nanoparticles, have been acquired in order 
to detect the presence of protein. In order to detect likely light-induced conformational 
changes in EGF, SYPRO® Orange was used as a molecular probe. Fluorescence 
emission spectra of SYPRO® Orange (excitation fixed at 470 nm) and fluorescence 
excitation spectra of SYPRO® Orange (emission fixed at 580 nm) were also acquired prior 
and after continuous illumination of EGF and EGF-conjugated HAOA-coated gold 
nanoparticles at 295 nm for 2 hours. Formation of Trp photoproducts (Kyn and NFK) upon 
295 nm excitation of free EGF and EGF-conjugated HAOA-coated gold nanoparticles has 
been confirmed using steady state fluorescence spectroscopy. In order to detect Kyn and 
NFK, fluorescence emission spectra were acquired upon 320 nm excitation of the solution 
before and after 2 hours of continuous illumination at 295 nm. In order to detect the 
presence of Kyn, emission spectra were obtained upon 360 nm excitation before and after 
295 nm continuous excitation. Fluorescence spectral changes have been quantified and 
compared for free and conjugated EGF. A fresh sample was used for each illumination 
run.  
 
2.5 Physical characterization of EGF-conjugated HAOA-coated gold nanoparticles 
Mean particle size, polydispersity index (PI) and zeta potential (ZP) for EGF-conjugated 
HAOA-coated gold nanoparticles were determined with a Coulter Nano-sizer Delsa 
Nano™C (Fullerton, CA). A low value of PI factor (< 0.25) will indicate a less dispersed 
nanoparticles distribution in size. “D-value” was determined as the size distribution in 
10%, 50% and 90% of the nanoparticles population [29]. EGF-conjugated HAOA-coated 
gold nanoparticles were characterized by UV-visible spectroscopy (Evolution 600, UK) 
and the respective maximum absorbance wavelength (λmax) was determined. 
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2.6 TEM analysis of EGF-conjugated HAOA-coated gold nanoparticles 
Structure and surface morphology of EGF-conjugated HAOA-coated gold nanoparticles 
were analyzed by Transmission Electron Microscopy (TEM, Zeiss M10, Germany). 
Samples were prepared through “sequential two-droplet” method by re-suspending the 
nanoparticles in distilled water and placing a drop (5-10 µL) of the suspension on to a 
formvar grid for 30-60 sec. When the nanoparticles suspension had partly dried, the 
surface of the grid was washed three times with distilled water and the excess of water 
was removed with a filter paper. Then, sodium phosphotungstate (PTA, 2%, w/v) was 
applied to the grid for 10 sec, the excess of stain removed with a filter paper and the grid 
was left to dry at room temperature for 24 hours. Samples were analyzed at voltage 
setting of 60 kV. Different fields of the images were recorded digitally. 
 
2.7 Confocal fluorescence microscopy studies with EGF-conjugated HAOA-coated 
gold nanoparticles 
EGF-conjugated HAOA-coated gold nanoparticles were marked with two different 
fluorescent probes, Coumarin-6 and Alexa Fluor 647, as described below, for confocal 
microscope visualization and colocalization. Firstly, an aliquot (20 µL) of a saturated 
solution of Coumarin-6 (λmax_ex = 460 nm, λmax_em = 500 nm) in ethanol was added to an 
aqueous suspension, containing the polymer HAOA and the gold nanoparticles at 1:1 
(v/v). Then, EGF marked with Alexa Fluor 647 (λmax_ex = 650 nm, λmax_em = 665 nm) was 
added to the HAOA-coated gold nanoparticles suspension. Coumarin-6 labeled 
nanoparticles were allowed to conjugate with the EGF-Alexa Fluor 647 for 30 min at 
room temperature, and were left 24 hours at 4 ºC, protected from the light. The 
suspension was centrifuged twice at 500 x g for 20 min in a FV2400 Microspin (BioSan, 
Riga, Latvia) to remove unbound EGF. The pellet was re-suspended in PBS buffer (pH 
7.4). Confocal Laser Scanning Microscopy (CLSM, Leica, SP5, Mannheim, Germany) 
was used to verify the colocalization of both dyes on the EGF-conjugated HAOA-coated 
gold nanoparticles. The chosen excitation laser line He-Ne was 561 nm and the 
fluorescence emission selected range was set to 569-666 nm. Each sample was 
analyzed at room temperature and upon letting it dry on a glass slide. Different fields of 
the images were recorded digitally.  
 
2.8 Circular dichroism spectroscopy  
Far UV circular dichroism (CD) spectroscopy was carried out to detect any changes in 
EGF secondary structure after conjugation with HAOA-coated gold nanoparticles using 
a Jasco J-720 spectropolarimeter (Jasco Corporation, Easton, MD, USA), with a 
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photomultiplier suitable for the 200-700 nm range. After calibration to remove the noise 
of the device, the PBS buffer used to prepare the native EGF solution and Milli-Q water 
used for nanoparticles formulations were used as references to obtain the respective 
baselines. Far UV spectra were acquired using a quartz cell containing solutions of free 
EGF (0.3 mg/mL), EGF-conjugated HAOA-coated gold nanoparticles (16.5 µg/mL) and 
HAOA-coated gold nanoparticles (without peptide). Furthermore, spectra of EGF 
extracted from HAOA-coated gold nanoparticles by two different methods were 
recorded: 1) EGF non-conjugated present in the supernatant after centrifugation of EGF-
conjugated HAOA-coated gold nanoparticles at 7200 x g for 10 min and 2) after 
incubation of EGF-conjugated HAOA-coated gold nanoparticles in PBS pH 5.5, at 37ºC, 
for 72 hours, followed by centrifugation at 9000 x g for 3 min. Scanning of each sample 
was conducted from 200 nm to 260 nm with a resolution of 1 nm band width, 3 
accumulations, scan speed 100 nm/min and 2 seconds response time. Data was 
processed using 10 point smoothing in Origin 8.1 (OriginLab Corporation, Northampton, 
MA, USA). 
 
2.9 Cytotoxicity assays in HaCaT cell line model 
Cell viability studies were conducted in human immortalized keratinocytes (HaCaT) 
using the MTT assay [30,31] in order to assess the cytotoxicity of EGF-conjugated 
HAOA-coated gold nanoparticles. Cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin solution. HaCaT cells were seeded onto 96-well plate at a density 
of 5,000 cells/ well to reach the desired confluence. EGF-conjugated HAOA-coated gold 
nanoparticles were tested at different concentrations: 0-80 µM (based on the 
concentration of gold). DMSO 5% (v/v) was used as the positive control. Cells were 
exposed to nanoparticle suspension for 24 hours. After this period, cells were washed 
twice with PBS and incubated with MTT solution (0.5 mg/mL in culture medium) for 2.5 
hours at 37 ºC. Culture medium was then removed and cells were washed again with 
PBS. DMSO (200 µL per well) was added to dissolve the formazan crystals and 
absorbance was read at 595 nm (Thermo Scientific Multiskan FC, Shanghai, China). 
Three to four independent experiments were carried out, each comprising four replicate 
cultures. 
 
2.10 EGFR binding assay on A549 cells GFP-EGFR  
In vitro studies were carried out in A549 cells, in which the genomic EGFR gene has 
been endogenously tagged with a Green Fluorescent Protein gene (GFP) (Sigma-Aldrich 
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ref. CLL1141), since this is a specific and well-studied cell model for EGFR binding assay 
[32]. A549 cells were cultured in DMEM medium with FBS 10% and 1 µg/mL puromycin 
and maintained at a 37 oC in a 5% CO2 atmosphere, in order to analyze the effects of 
adding free EGF (4 µg/mL), EGF-conjugated HAOA-coated gold nanoparticles (4 µg/mL 
EGF; 60 µM gold nanoparticles) and HAOA-coated gold nanoparticles (non-conjugated; 
60 µM). EGF-conjugated HAOA-coated gold nanoparticles were marked with two 
different fluorescent probes, Coumarin-6 (λmax_ex = 460 nm, λmax_em = 500 nm) and Alexa 
Fluor 647 (λmax_ex = 650 nm, λmax_em = 665 nm), as previously described, for confocal 
microscope visualization and colocalization experiments. Free EGF was marked with 
Alexa Fluor 647, while nanoparticles were labeled with Coumarin-6. Prior to the image 
acquisition in the confocal fluorescence microscope, the cells were incubated 1.5 hours 
with the free EGF and with the EGF-conjugated HAOA-coated gold nanoparticles. In 
specific wells, a primary mouse monoclonal antibody anti-EGFR (1 µg/mL of neutralizer 
antibody LA1, Millipore (05-101)) was used to block EGFR. After 1 hour of incubation 
with the antibody, free EGF or EGF-conjugated HAOA-coated gold nanoparticles were 
added to the A549 cells’ incubation medium, for incubation during 1.5 hours, to see if 
they compete for the receptor binding and consequent receptor internalization. As 
controls, non-treated cells and HAOA-coated gold nanoparticles loaded with Coumarin-
6 (without EGF) were used. EGFR binding and activation was analyzed by confocal 
fluorescence microscopy (CLSM, Leica, SP5, Mannheim, Germany). Ligand binding to 
EGFR activates the receptor and the GFP tagged receptor initially localized on the cell 
membranes, is then internalized. This leads to the appearance of fluorescence granules 
in the cell cytoplasm, as described previously for Human EGFR Live Cell Fluorescent 
Biosensor Assay (Sigma-Aldrich, Germany).  
 
2.11 Data Analysis 
All data analysis, plotting and fitting procedures were done using Origin 8.1 (OriginLab 
Corporation, Northampton, MA, USA). 
 
2.11.1 Emission Spectra and Excitation Spectra 
Emission and excitation spectra were first smoothed using a 10 points adjacent 
averaging. All fluorescence spectra obtained were first Raman corrected by subtracting 
the spectra recorded for the buffer in solution. Normalized emission and excitation 
spectra were obtained by dividing each data point by the maximum intensity value in 
each spectrum. 
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2.11.2 Fitting Procedures 
2.11.2.1 EGF fluorescence emission kinetic traces (em. at 330 nm) upon 295 nm 
continuous excitation as a function of light power and temperature 
Each decay curve acquired upon 2 hours of continuous 295 nm illumination of EGF 
exposed at different temperatures (10 ºC, 15 ºC, 20 ºC, 25 ºC and 30 ºC) and different 
excitation slit openings (0.5 mm, 0.8 mm, 1.2 mm and 2.0 mm), was fitted using a single 
exponential decay model given by the function F(t) = C1*exp(-x*k1) + y0 or a double 
exponential decay model, according to F(t)=y0+C1*exp(-k1*x)+C2*exp(-k2*x). F(t) is the 
fluorescence emission intensity at 330 nm (a.u.) upon 295 nm at excitation time t (min), 
y0, C1 and C2 are constants and k1, k2 are the rate constant of fluorescence emission 
intensity decrease (min-1); y0 value was fixed to 0. Root mean square error R2 was > 0.99 
for all fitted traces. A double exponential decay model was selected if the single decay 
model did not provide a good fit. Data obtained with 0.1 mm slit size, was fitted using a 
linear model (F(t)=y0+C1*x). A good fit was based on the errors associated to the different 
parameters and the root mean square error. Fitted parameter values and corresponding 
errors, and root mean square error values obtained after fitting the 330 nm emission 
kinetic traces are displayed in Tables 2 and 3.  
 
2.11.2.2 EGF photochemistry: Arrhenius plot and activation energy  
Temperature dependence of the decay constant of the EGF kinetic traces (Fig. 2A) 
(where the fluorescence emission intensity at 330 nm is displayed upon 295 nm 
excitation), was analyzed using four different temperatures: 15 ºC, 20 ºC, 25 ºC and 30 
ºC. Data was fitted according to the logarithmic form of the Arrhenius equation: ln k = ln 
A0 + (Ea/RT), where A0 is the pre-exponential factor, Ea is the activation energy, R is the 
universal constant for perfect gases (R = 8.314 J/ mol.K) and T is the temperature (in 
Kelvin). The Arrhenius plot and extracted parameters are displayed in Fig. 3. 
 
2.11.2.3 Free EGF and EGF conjugated HAOA–coated gold nanoparticles fluorescence 
kinetics (em. at 330 nm) upon 295 nm excitation 
Fluorescence emission intensity kinetic traces at 330 nm for free EGF, plain non-coated 
gold nanoparticles, HAOA-coated gold nanoparticles and EGF-conjugated HAOA-
coated gold nanoparticles samples are displayed in Fig. 5. Traces were acquired upon 
continuous 295 nm illumination for 2 hours, at 20 ºC, except for plain gold nanoparticles 
and HAOA-coated gold nanoparticles without EGF, which were illuminated for 1 hour. All 
traces were fitted using a double exponential decay model according to the formula 
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F(t)=y0+C1*exp(-k1*x)+C2*exp(-k2*x). F(t) is the fluorescence emission intensity at 330 
nm (a.u.) upon 295 nm excitation at time t (min), y0, C1 and C2 are constants and k1 and 
k2 is the rate constant of fluorescence emission intensity decrease (min-1); y0 value was 
fixed to 0. The root mean square error R2 was > 0.99 for all kinetics. The fitted parameter 
values and corresponding errors, and root mean square error values obtained after fitting 
the 330 nm emission kinetic traces are displayed in Table 4.  
 
 
3. Results 
 
Fig. 1 displays the 3D molecular structure of Epidermal Growth Factor, EGF (1JL9.pdb). 
Although EGF is formed by two amino acid chains (A and B), only chain B is represented. 
Tryptophan (Trp), Tyrosine (Tyr) residues and disulphide bridges (SS) are highlighted in 
red, blue and green, respectively. In total, EGF has 2 Trp residues, 5 Tyr residues and 3 
SS bridges. Table 1 lists the shortest distances between each Trp and Tyr residues and 
the nearest SS bonds. The shortest distance between Tyr13 (atom CD1) and the SS 
bridge C14-C31 is 4.4 Å. All considered distances were < 12 Å. In addition, EGF has no 
Phenylalanine (Phe) residues but has a considerable number of Arginine (Arg) residues 
in its structure, close to Trp residues. Arg residues are of considerable importance since 
they quench the aromatic residues fluorescence emission, when the NH2 groups become 
protonated. The closest distances between these two amino acids occur between Arg45 
(NE) and Trp50 (CH2) and Trp49 (CE3) at 4.5 Å and 7.5 Å, respectively.  
 
 
 
 
Figure 1.Molecular structure of EGF (chain B) according to (1JL9.pdb). Aromatic 
residues are represented by different colors: Trp (red), Tyr (blue) and Cys (green).  
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Table 1. Shortest spatial distances between disulphide (SS) bonds and aromatic 
residues (tryptophan and tyrosine) in EGF chain B (1JL9.pdb). The shortest distances (< 
12 Å) between atoms of each pair of elements (Trp, Tyr and disulphide bonds) were 
considered. For Trp and Tyr residues, only atoms belonging to the indole and benzene 
rings were considered, and for SS bonds one of the SG atoms. (W = Trp; Y = Tyr; PDB 
atomtype descriptor used is given in parentheses). 
 
Disulphide Bond Aromatic Residue Distance (Å) 
C6-C20 Y13 (CD1) 5.5 
 Y22 (CG) 9.2 
 Y29 (CD1) 4.8 
C14-C31 Y13 (CD1) 4.4 
 Y29 (CD1) 9.5 
 Y37 (CD2) 9.7 
 Y44 (CD2) 11.8 
C33-C42 Y13 (CD1) 7.9 
 Y37 (CG) 5.7 
 Y44 (CD2) 9.5 
 W49 (CZ3) 7.3 
 
Figs. 2A and 2B display the fluorescence kinetic traces for EGF upon 2 hours excitation 
at 295 nm (emission fixed at 330 nm) and for SYPRO® Orange an analogous experiment 
(excitation of 470 nm and emission fixed at 580 nm), respectively. Traces were acquired 
at five different temperatures: 10 ºC, 15 ºC, 20 ºC, 25 ºC and 30 ºC. At all temperatures, 
fluorescence emission intensity of Trp is observed to decay as a function of illumination 
time. On the other hand, fluorescence emission intensity of SYPRO® Orange increases 
with illumination time. The parameters and corresponding errors, as well as root mean 
square error values, obtained after fitting each kinetic trace are displayed in Table 2. At 
10 ºC and 15 ºC, EGF showed similar fluorescence emission decays with a decrease in 
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Trp fluorescence emission intensity at 330 nm of 56.2%, 52.8%, respectively. The 
corresponding increase in the fluorescence emission of SYPRO® Orange after 2 hours 
excitation of EGF at 295 nm at 10 ºC and 15 ºC was 15.6% and 22.7%, respectively. At 
20 ºC and 30 ºC, the fluorescence emission intensity of Trp decreased 59.6% and 59.1%, 
respectively, after 2 hours excitation of EGF at 295 nm, while the fluorescence emission 
intensity of SYPRO® Orange increased 2.3% and 17.3%, respectively. At last, 
continuous 295 nm excitation of EGF at 25 ºC led to a 59.7% decrease in the 
fluorescence emission intensity of the protein and to a 6.7% increase in the fluorescence 
emission intensity of SYPRO® Orange.  
 
 
 
Figure 2.Temperature effect on EGF photochemistry: A) EGF fluorescence excitation 
and emission wavelengths were fixed at 295 nm and 330 nm, respectively, at 10 ºC, 15 
ºC, 20 ºC, 25 ºC and 30 ºC; B) SYPRO® Orange fluorescence excitation and emission 
wavelengths were fixed at 470 nm and 580 nm, at the same temperatures. Continuous 
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illumination was conducted during 2 hours and the excitation slit size was set at 0.8 mm 
(1.67 µW) for all experiments.  
 
Table 2.Single exponential fit using model F(t) = C1*exp(-x*k1) + y0 for each decay curve 
of EGF at 10 ºC, 15 ºC, 20 ºC and 30 ºC. For the decay curve of EGF at 25 ºC, a double 
exponential fit using model F(t)=y0+C1*exp(-k1*x)+C2*exp(-k2*x) was selected (see 
Fig.2A). Fit parameters are displayed in this table. Adj. R2 stands for Adjusted R- Square. 
 
Decay Parameters Statistic 
 y0 C1 C2 k1 k2 
Adj. 
R2 
10 ºC 7.1E+4±1.5E+2 1.0E+6±1.4E+2 - 1.1E+3±4.7 - 0.999 
15 ºC 7.2E+4±1.5E+2 9.8E+4±1.4E+2 - 1.1E+3±6.2 - 0.999 
20 ºC 7.7E+4±2.0E+2 1.2E+5±2.4E+2 - 2.2E+3±1.3E+1 - 0.999 
25 ºC 5.6E+4±3.9E+2 4.3E+4±5.9E+2 7.1E+4±3.1E+2 2.8E+2±4.1 1.7E+3±3.0E+1 0.999 
30 ºC 6.3E+4±1.7E+2 9.0E+4±2.8E+2 - 7.5E+2±5.9 - 0.997 
 
In Fig. 3 is displayed the Arrhenius plot. Due to the temperature dependence of the EGF 
rate constant (k), recovered from the fluorescence emission decays at 330 nm (excitation 
at 295 nm), at the five different temperatures studied, we obtained an activation energy 
(Ea) and a pre-exponential factor (A0) of 19.9±0.9 kJ.mol-1 and 0.44±0.37 s-1, respectively. 
The equation obtained was y = -1.1x – 1933.4 (R2= 0.994). 
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Figure 3. Arrhenius plot showing the linear correlation between the logarithm of the 
kinetic rate constant (ln k) and the inverse of temperature 1/T (ln k = ln A0 - Ea/RT), R2 = 
0.994). The activation energy (Ea) and the pre-exponential factor (A0) were 19.9±0.9 
kJ.mol-1 and 0.44±0.37 M-1.s-1, respectively. Uncertainty errors for ln k values are 
represented as error bars (percent of data: 1%).  
 
In Figs. 4A and 4B are displayed, respectively, the kinetic traces for free EGF during 2 
hours excitation at 295 nm (emission at 330 nm) at 20 ºC and the kinetic traces for 
SYPRO® Orange (excitation of 470 nm and emission at 580 nm) using different excitation 
powers. Excitation of free EGF at 295 nm for 2 hours with different excitation slit sizes of 
0.1 mm, 0.5 mm, 0.8 mm, 1.2 mm and 2.0 mm led to a 8.0%, 48.6%, 59.6%, 65.6% and 
70.8% decrease in Trp fluorescence emission intensity, respectively. After 295 nm 
excitation of EGF for 2 hours, the fluorescence emission intensity of SYPRO® Orange 
increases 9.1%, 2.3%, 21.5% and 6.1% for slit sizes of 0.5 mm, 0.8 mm, 1.2 mm and 2.0 
mm, respectively. In the same experiments, the fluoresce emission intensity of SYPRO® 
Orange has maximally increased by 9.1%, 3.2%, 26.8% and 19.3% for 0.5 mm, 0.8 mm, 
1.2 mm and 2.0 mm, respectively. No change was observed in the fluorescence emission 
intensity of SYPRO® Orange at a slit size of 0.1 mm (decrease: 0.2% = ~0%). A single 
exponential model (F(t) = y0 +C1*exp(-x*k1)) was selected to fit the 330 nm decay curves 
obtained with 0.5 mm and 0.8 mm slit openings. The traces obtained with larger slit 
openings (1.2 mm and 2.0 mm) were fitted with a double exponential model 
(F(t)=y0+C1*exp(-k1*x)+C2*exp(-k2*x)). The corresponding fitted parameter values (C1, C2 
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k1, k2, y0) and corresponding errors, as well as root mean square error values, are 
displayed in Table 3. The 330 nm fluorescence decay obtained when a slit 0.1 mm was 
chosen was best fitted by a linear model.   
 
 
 
Figure 4. UV-light power effect (different excitation slit openings) on EGF 
photochemistry: A) EGF fluorescence excitation and emission wavelengths were fixed 
at 295 nm and 330 nm, respectively, for 0.1 mm (0.12 µW), 0.5 mm (0.30 µW), 0.8 mm 
(1.67 µW), 1.2 mm (2.34 µW) and 2.0 mm (4.40 µW); B) SYPRO® Orange fluorescence 
excitation and emission wavelengths were fixed at 470 nm and 580 nm, for the same 
power levels. Continuous illumination was conducted during 2 hours and the temperature 
of each solution was kept at 20 °C for all experiments. 
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Table 3. Single exponential fit using model F(t) = C1*exp(-x*k1) + y0 for each decay curve 
of EGF at a power slit size of 0.5 mm and 0.8 mm (corresponding to 0.30 µW and 1.67 
µW, respectively) and double exponential fit using model F(t)=y0+C1*exp(-k1*x)+C2*exp(-
k2*x) for each decay curve of EGF at a power slit size of 1.2 mm and 2.0 mm 
(corresponding to 2.34 µW and 4.40 µW, respectively) (see Fig.4A). For slit 0.1 mm (0.12 
µW), a linear model was selected. Fit parameters are displayed in this table. R2 stands 
for Adjusted R- Square. 
 
Slit (mm) Decay Parameters Statistic 
 y0 C1 C2 k1 k2 R2 
0.1 1.8E+4±1.1E+1 -0.16±2.7E-3 - - - 0.921 
0.5 5.7E+4±1.2E+2 6.2E+4±1.0E+2 - 3.0E+4±1.5E+1 - 0.999 
0.8 7.7E+4±2.0E+2 1.2E+5±2.4E+2 - 2.2E+3±1.3E+1 - 0.999 
1.2 5.8E+4±1.1E+4 9.0E+4±5.6E+3 1.2E+5±5.5E+3 7.9E+3±2.1E+3 1.2E+3±3.7E+1 0.999 
2.0 9.8E+4±1.8E+3 2.2E+5±1.3E+3 1.2E+5±6.4E+2 6.8E+2±4.9 5.1E+3±2.1E+2 0.999 
 
After studying the temperature and power dependence of the kinetic traces for free EGF, 
the behavior of this peptide has been monitored after conjugation with a nanosystem 
made of a gold core and a biodegradable polymeric coating of HAOA. HAOA-coated gold 
nanoparticles (i.e., non-conjugated with EGF) showed a mean particle size of 300 nm 
(PI: 0.2) and a negatively charged surface (-19 mV) [24]. After conjugation with EGF, the 
volume distribution for 90% of HAOA-coated gold nanoparticles (D 90%) was 220 nm, 
as confirmed by TEM analysis, where EGF-conjugated HAOA-coated gold nanoparticles 
showed a size around 100-200 nm and a spherical morphology (see Fig. 5). EGF-
conjugated HAOA-coated gold nanoparticles are displayed, both as an illustration (upper 
left corner) and when imaged by TEM. EGF-conjugated HAOA-coated gold 
nanoparticles are composed by a dense gold core observed in the TEM image as a dark 
core, and by a soft polymeric coating of HAOA on the surface, visible in the TEM image 
as a grey area around the core. EGF may be associated to the HAOA coating of the gold 
nanoparticles as illustrated. Zeta potential of EGF-conjugated HAOA-coated gold 
nanoparticles was around -5 mV when compared to the lower value of -19 mV for the 
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HAOA-coated gold nanoparticles alone. EGF-conjugated HAOA–coated gold 
nanoparticles showed a spherical morphology with the polymeric coating envelope. In 
addition, a maximum absorbance peak at 655 nm compared to 800 nm observed for the 
plain non-coated gold nanoparticles, indicating that a 145 nm blue shift has occurred 
after conjugation.  
 
 
 
Figure 5. EGF conjugated HAOA-coated gold nanoparticles represented as an 
illustration (upper corner) and as the TEM image at scale bar of 250 nm. 
 
In Fig. 6, the EGF fluorescence emission intensity at 330 nm during 2 hours of continuous 
295 nm excitation is displayed and compared for free EGF, EGF-conjugated HAOA-
coated gold nanoparticles, empty HAOA–coated gold nanoparticles and non-coated 
plain gold nanoparticles, exposed to a 1 hour excitation at 295 nm (emission fixed at 330 
nm). Plain gold nanoparticles (i.e., without HAOA coating) and HAOA-coated gold 
nanoparticles were used as controls. The double exponential fit model (F(t)=yo+C1*exp(-
k1*x)+C2*exp(-k2*x)) used to fit the kinetic traces for free EGF and EGF-conjugated 
HAOA-coated gold nanoparticles showed that the fluorescence emission intensity of free 
EGF decayed faster than the one for conjugated EGF with HAOA-coated gold 
nanoparticles. For free EGF, k1 and k2 were, respectively, k1 = 6.8E+2 ± 4.9 min-1and k2 
= 5.1E+3 ± 2.1E+2 min-1, while for EGF-conjugated HAOA-coated gold nanoparticles, k1 
and k2 were, respectively, k1= 4.3E+2 ± 1.8E+1 min-1 and k2= 3.9E+3 ± 2.3E+2 min-1. 
Decay constants for conjugated EGF were 1.5-fold (k1) and 1.3-fold (k2) lower compared 
to the ones for free EGF. Also, the initial Trp 330 nm fluorescence emission intensity 
(excitation at 295 nm) for EGF-conjugated HAOA-coated gold nanoparticles is almost 
three times lower than the initial fluorescence emission intensity of free EGF.  Fitting 
results are represented in Table 4. 
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Figure 6. EGF fluorescence emission intensity at 330 nm for free EGF (2 hours 295 nm 
excitation), EGF-conjugated HAOA-coated gold nanoparticles (2 hours 295 nm 
excitation), and empty HAOA-coated gold nanoparticles and non-coated plain gold 
nanoparticles (1 hour 295 nm excitation). All samples were analyzed at 20 ºC and 
excitation slit size fixed at 2.0 mm (4.40 µW).  
 
Table 4. Double exponential fit using model F(t)=yo+C1*exp(-k1*x)+C2*exp(-k2*x) for free 
EGF, EGF-conjugated HAOA-coated GNP (gold nanoparticles), plain non-coated GNP 
(control) and HAOA-coated GNP (control) (see Fig. 5). Fit parameters are displayed in 
this table. Adj. R2 stands for Adjusted R- Square. 
 
Samples Constants (y0, k1, k2) Adj. R2 
Pre-exponential factors 
(C1, C2) 
Free EGF 
y0 = 9.8E+4 ± 1.8E+3 
k1 = 6.8E+2 ± 4.9 
k2 = 5.1E+3 ± 2.1E+2 
0.999 
C1 =2.2E+5 ± 1.3E+3 
C2 =1.2E+5 ± 6.4E+2 
EGF – conjugated 
HAOA GNP 
y0 = 1.2E+5 ± 4.4E+2 
k1= 4.3E+2 ± 1.8E+1 
k2= 3.9E+3 ± 2.3E+2 
0.996 
C1=1.8E+4 ± 4.4E+2 
C2=2.2E+4 ± 2.2E+2 
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Plain non-coated 
GNP (control) 
y0 = 7.7E+4 ± 1.0E+3 
k1= 5.7E+2 ± 5.2E+1 
k2=6.5E+3 ± 5.2E+2 
0.997 
C1=6.2E+3 ± 3.7E+2 
C2=2.6E+4 ± 6.6E+2 
    
HAOA-coated 
GNP 
(control) 
y0= 8.9E+4 ± 1.0E+3 
k1= 3.5E+2 ± 8.7E+1 
k2= 7.6E+3 ± 7.1E+2 
0.989 
C1=2.1E+3 ± 2.6E+2 
C2=1.8E+4 ± 8.1E+2 
 
Fig. 7 displays the effect of conjugation on the fluorescence spectra of EGF. 
Fluorescence excitation spectra (emission fixed at 330 nm) and fluorescence emission 
spectra (excitation fixed at 295 nm) were compared for free EGF in supernatant, EGF-
conjugated HAOA–coated gold nanoparticles (before centrifugation) and EGF-
conjugated HAOA–coated gold nanoparticles (after centrifugation) (see Fig. 7A). 
Experiments were carried out at 20 ºC, with a fixed excitation slit of 2.0 mm (power: 4.40 
µW) and EGF was only illuminated with the light necessary for obtaining the represented 
spectra. Centrifugation at 500 x g for 20 min was essential for the elimination of the non-
conjugated EGF. Isolated EGF-conjugated HAOA–coated gold nanoparticles (after 
centrifugation) showed a clear emission peak at 326 nm, which confirms the presence 
of Trp residues at the HAOA–coated gold nanoparticles’ surface (see Fig. 7B). 
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Figure 7. A) Conjugation effect: EGF in supernatant (after conjugation) compared with 
free EGF and EGF-conjugated HAOA-coated gold nanoparticles; B) EGF-conjugated 
HAOA-coated gold nanoparticles, at different scale bar. Fluorescence excitation spectra 
was fixed at 330 nm and fluorescence emission spectra was fixed at 295 nm. 
Experiments were conducted at 20 ºC and excitation slit size fixed at 2.0 mm (4.40 µW). 
No continuous excitation of EGF was conducted, beside the necessary for obtaining the 
represented spectra. 
 
Figs. 8 and 9 display the fluorescence excitation and emission spectra of EGF, as free 
peptide and as conjugated with HAOA-coated gold nanoparticles, and of SYPRO® 
Orange, acquired before and after 2 hours of 295 nm illumination. The fluorescence 
emission and excitation intensity of SYPRO® Orange is 10 and 18.6 higher, respectively, 
when added to EGF-conjugated HAOA-coated gold nanoparticles than when added to 
free EGF. After 2 hours of illumination, free EGF excitation intensity at 284 nm decreased 
81.2%, while EGF-conjugated HAOA-coated gold nanoparticles excitation intensity, at 
474 nm, decreased 41.0%. Fluorescence emission intensity of free EGF at 328 nm 
decreased 74.8%, after illumination, and a blue shift occurred from 344 nm to 328 nm, 
while the fluorescence emission intensity of EGF-conjugated HAOA-coated gold 
nanoparticles at 347 nm decreased 25.7%. After 295 nm illumination of free EGF for 2 
hours, fluorescence excitation intensity of SYPRO® Orange increased 10.7%. On the 
other hand, fluorescence excitation intensity of SYPRO® Orange after 2 hours of 295 nm 
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illumination of EGF-conjugated HAOA-coated gold nanoparticles decreased 40.9%. 
Fluorescence emission intensity of SYPRO® Orange decreased 21.4% and 23.8% after 
illumination of both free EGF and EGF-conjugated HAOA-coated gold nanoparticles, 
respectively. Interestingly, the fluorescence emission spectra of SYPRO® Orange 
showed a blue shift (from 610 nm to 594 nm) when added to free EGF, while when added 
to EGF-conjugated HAOA-coated gold nanoparticles, the peak of SYPRO® Orange 
emission spectra showed a red shift from 584 nm to 628 nm (see Fig. 9).  
 
 
 
Figure 8. EGF fluorescence excitation and emission spectra acquired before and after 
295 nm illumination for 2 hours. Trp fluorescence excitation and emission wavelengths 
were fixed at 295 m and 330 nm, respectively. Excitation slit size was set at 2.0 mm (4.40 
µW) and the temperature of each solution was kept at 20 °C for all experiments. 
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Figure 9. SYPRO® fluorescence excitation and emission spectra acquired before and 
after EGF 295 nm illumination for 2 hours. SYPRO® Orange fluorescence excitation and 
emission wavelengths were fixed at 470 nm and 580 nm, respectively. Excitation slit size 
was set at 2.0 mm (4.40 µW) and the temperature of each solution was kept at 20 °C for 
all experiments.  
 
In order to detect the putative presence of photochemical species such as NFK and Kyn, 
fluorescence emission spectra upon 320 nm excitation were acquired for free EGF and 
for EGF-conjugated HAOA-coated gold nanoparticles, before and after 295 nm 
continuous illumination of the samples (see Fig. 10A). HAOA-coated gold nanoparticles 
spectra, before and after 2 hours illumination at 295 nm, were used as controls. For free 
EGF, a peak centered at 418 nm was observed upon 320 nm excitation. The 
fluorescence emission intensity of the peak increases 51.0% after continuous excitation 
with 295 nm for 2 hours. For EGF-conjugated HAOA-coated gold nanoparticles, two 
peaks were observed: a peak centered at 392 nm and a larger peak at 598 nm. The 
second peak at 596-598 nm is also visible for the controls HAOA-coated gold 
nanoparticles, without EGF, before and after continuous illumination, though 3 to 4 times 
less intense. After continuous excitation with 295 nm for 2 hours, the fluorescence 
emission intensity decreased by 14.8% and 5.8%, for the peak centered at 392 nm and 
598 nm, respectively. In Fig. 10B are displayed the fluorescence emission intensity 
spectra upon 360 nm excitation in order to detect the putative presence of the 
photochemical species Kyn and NFK. HAOA-coated gold nanoparticles spectra, before 
and after 2 hours illumination at 295 nm, were used as controls. For free EGF, a peak 
centered at 460 nm is observed upon 360 nm excitation. The fluorescence emission 
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intensity of the peak increases 127% after continuous excitation with 295 nm for 2 hours. 
Two emission peaks were observed for EGF-conjugated HAOA-coated gold 
nanoparticles: a peak centered at 461 nm and a larger peak at 580 nm. The second peak 
at 580 nm is also visible for the control HAOA-coated gold nanoparticles, without EGF, 
before and after continuous illumination, but with less intensity, like observed upon 320 
nm excitation. After continuous excitation with 295 nm for 2 hours, the fluorescence 
emission intensity decreased by 5.7% and 40.8%, for the peak centered at 461 nm and 
580 nm, respectively. 
 
 
 
Figure 10. A) Fluorescence emission spectra for NFK + Kyn, before and after excitation 
of free EGF and EGF-conjugated HAOA-coated gold nanoparticles, at a fixed 
wavelength of 320 nm. Experiments were conducted at 20 ºC and excitation slit size 
fixed at 2.0 mm (4.40 µW); B) Fluorescence emission spectra for Kyn + NFK, before and 
after excitation of free EGF and EGF-conjugated HAOA-coated gold nanoparticles, at a 
fixed wavelength of 360 nm. Experiments were conducted at 20 ºC and excitation slit 
size fixed at 2.0 mm (4.40 µW). 
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In Fig.11 is displayed the fluorescence emission of EGF-conjugated HAOA-coated gold 
nanoparticles. EGF labeled with Alexa Fluor 647 appears in red and HAOA-coated gold 
nanoparticles labeled with Coumarin-6 appear in green. Colocalization of both dyes, and 
therefore of EGF and HAOA-coated gold nanoparticles, is displayed in yellow. The 
sample was imaged in a confocal microscope (scale bar at 5 µm). Some aggregation is 
observed.  
 
 
 
Figure 11. Colocalization of HAOA-coated gold nanoparticles conjugated with EGF. 
EGF was dyed with Alexa Fluor 647 (red color) and HAOA-coated gold nanoparticles 
were dyed with Coumarin-6 (green color). The parts were the HAOA-coated gold 
nanoparticles are associated with EGF, in the same localization, are visible in yellow 
(scale bar at 5 µm). 
 
Circular dichroism (CD) is a good method to evaluate changes in the secondary structure 
of proteins. Fig. 12 shows far UV CD spectra collected for different samples.  The spectra 
show that after conjugation with HAOA-coated gold nanoparticles EGF maintains its 
secondary structure. Although free EGF (non conjugated) has a signal of higher intensity 
than the rest of the studied samples (i.e., EGF-conjugated HAOA-coated gold 
nanoparticles, EGF in supernatant and extracted EGF with acidic pH solution), its 
concentration was also 18 times higher. The CD spectra indicate that EGF probably has 
a secondary structure, with contributions from different secondary elements. This is 
suggested by the presence of a negative peak around 208 - 210 nm, characteristic of α-
helix structure. However, the negative band at 220 nm, also characteristic of α-helix 
structure was not detected. The absence of CD bands above 215 – 220 nm range 
suggests the presence of EGF’s β- sheets.   
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Figure 12. The CD spectra of: free EGF (0.3 mg/mL), HAOA coated gold nanoparticles 
(without EGF), EGF-conjugated HAOA-coated gold nanoparticles (16.5 µg/mL), non- 
conjugated EGF in supernatant, extracted by centrifugation, and EGF extracted after 
incubation of EGF-conjugated HAOA-coated gold nanoparticles in phosphate buffer pH 
5.5, at 37 ºC, for 72 hours.  
 
In Fig. 13 is represented the cell viability of human keratinocytes (HaCaT) exposed to 
EGF-conjugated HAOA-coated nanoparticles for 24 hours. No aggregates were visible 
after addition of the nanoparticles to the plaque wells. EGF has slightly promoted HaCaT 
growth at lowest concentrations (1-35 µM). EGF-conjugated HAOA-coated gold 
nanoparticles at 80 µM the highest concentration tested, showed a cell viability of around 
75% of that of non-treated control cultures.  
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Figure 13.Viability (%) of HaCaT cells exposed to EGF-conjugated HAOA-coated gold 
nanoparticles for 24 hours, assessed by MTT assay (n=3-4; mean ± SD).  
 
Fig.14 displays the results from the EGFR binding assay carried out with human lung 
carcinoma A549 cells. Images were taken 1.5 hours after the cells being in contact with 
EGF and for the negative control. Three different samples were tested: free EGF labeled 
with Alexa Fluor 647 (A1); EGF-conjugated HAOA-coated gold nanoparticles, being EGF 
labeled with Alexa Fluor 647 (B1); and EGF-conjugated HAOA-coated gold 
nanoparticles, with EGF labeled with Alexa Fluor 647 and the HAOA-coated gold 
nanoparticles labeled with Coumarin-6 (C1). In addition, the same samples were tested 
after the cells were incubated for 1 hour with anti-EGFR antibody, in order to block the 
EGF receptors. Finally, two control groups were studied: CN1, corresponding to cells 
from the non-treated group (i.e., cells without the addition of EGF or nanoparticles and 
of the anti-EGFR antibody) and CN2, corresponding cells in presence of HAOA-coated 
gold nanoparticles (without dye or EGF conjugation). In panels A1, B1 and C1 it can be 
observed that EGF has induced EGFR internalization, alone and when conjugated with 
the HAOA-coated gold nanoparticles. Both free EGF and EGF-conjugated HAOA-coated 
gold nanoparticles (panels B1 and C1) entered the cells’ cytoplasm but not its nucleus. 
The anti-EGFR antibody blocked the binding of EGF to EGFR, preventing receptor 
internalization (panel A2); however, the EGF-conjugated HAOA-coated gold 
nanoparticles could still enter the cells (panels B2 and C2) despite the presence of the 
antibody. The controls (panels CN1 and CN2) confirm that in the absence of EGF and in 
the absence of nanoparticles there is no EGFR activation. 
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Figure 14. EGFR binding assay in A549 cell model, for 1.5 hours in contact with 
treatment (100X). CN1 corresponds to the non-treated cells, while CN2 shows the 
exposure to HAOA-coated gold nanoparticles (without any dye). As for the treatment 
groups: A1) free EGF with Alexa Fluor 647, B1) EGF-conjugated HAOA-coated gold 
nanoparticles (only EGF is marked with Alexa Fluor 647), and C1) EGF-conjugated 
HAOA-coated gold nanoparticles (both EGF and HAOA-coated gold nanoparticles are 
marked with Alexa Fluor 647 and Coumarin-6, respectively). For A2, B2 and C2, anti-
EGFR antibodies were added 1 hour before the addition of the tested samples.  
 
 
4. Discussion 
 
The presented data has shown that the structure of EGF (Fig. 1) can be modulated by 
UV-light (295 nm) and that the photochemical changes are reduced when EGF is bound 
to HAOA-coated gold nanoparticles (Fig. 6). Like other small proteins and peptides (e.g., 
cutinase, insulin, α-lactoalbumin) [1,4,33], EGF is an interesting model protein for 
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photostability studies due to the close spatial proximity between its aromatic residues 
and its disulphide (SS) bridges. SS bridges are key structural elements in small proteins 
[34], responsible for maintaining the proteins´ structure and therefore their function. 
Disruption of SS bonds induced by UV excitation of aromatic residues in those peptides 
will most likely destroy its structure and impair its function [1,4,33]. Table 1 lists the three 
SS bonds of EGF located in close spatial proximity to aromatic residues (Trp and Tyr). 
The observed close distances will allow for electron transfer between the aromatic 
residues and the SS bridges [4], leading to the disruption of such bridges. EGF is a 
peptide where these reactions will occur in the presence of UVB light leading to 
conformational changes and to loss of functionality.  
 
EGF is a natural ligand for EGFR with significant biomedical importance in cancer 
treatment and diagnostic [6]. Changes in the fluorescence spectra of the extrinsic 
fluorescence probe SYPRO® Orange confirmed structural changes of EGF induced by 
temperature (Fig. 2), prolonged illumination at 295 nm (Fig. 4) and pH, as its fluorescent 
emission is enhanced upon binding to hydrophobic regions of the protein [22]. 
Temperature-dependent time based photochemical studies (see Fig. 2A) show that EGF 
photochemistry and protein conformational space is temperature dependent, being 
similar at 10 ºC and 15 ºC, at 20 ºC and 30 ºC but distinct at 25 ºC. At 25 ºC, SYPRO® 
Orange appears to bind less to the peptide than at other temperatures, indicating that 
EGF has fewer hydrophobic surfaces exposed to the solvent. The Arrhenius plot (see 
Fig. 3) showed that the activation energy (Ea) associated with the photochemical 
reactions induced by 295 nm on EGF was 19.9±0.9 kJ.mol-1 (i.e., 4.76 kcal/mol). This 
value was similar to the one found for α-lactalbumin (Ea = 21.8±2.3 kJ.mol−1) [33]. Power-
dependent irradiation studies of EGF (see Fig. 4A) reveal that the larger the power used, 
the faster the kinetics associated with the fluorescence decays. A single exponential 
model was used to fit the Trp decay curves acquired with 0.30 µW and 1.67 µW (see 
Table 3) but for larger powers (2.34 µW and 4.40 µW) a double exponential model was 
needed. This shows that different photochemical processes are initiated at higher powers 
when compared to lower powers. Experiments carried out with SYPRO® Orange (see 
Fig. 4B) show the same trend. Conformational changes induced in EGF are larger when 
illumination was carried out with higher powers: when using a 2.0 mm slit size opening, 
the fluorescence emission intensity of SYPRO® Orange was higher than when working 
with a 0.1 mm slit, indicating that the extrinsic probe is in contact with a larger 
hydrophobic surface rendered accessible due to light induced conformational changes.  
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Conjugation of EGF to HAOA-coated gold nanoparticles protected EGF from 
photochemistry (Fig. 6, Table 4): the presence of the particles decreased the rate of the 
light induced fluorescence changes and induced quenching. Both HA, OA and gold are 
known to be fluorescence quenchers. EGF has a promising therapeutic value as a 
targeting ligand for tumors overexpressing EGFR, such as melanoma [8,9]. Therefore, it 
has been coupled to nano-sized delivery systems, made of either and both metallic and 
polymeric materials [35–39]. The photochemical protection conferred by nanoparticulate 
carriers is advantageous. 
 
Gold nanoparticles were prepared according to a seed-growth method [40]. An aqueous 
extract of Plectranthus saccatus (Benth.), rich in anti-oxidative compounds (e.g., 
rosmarinic acid, caffeic acid and chlorogenic acid [41]), was used as the main reducing 
and capping agent. Furthermore, a coating made of hyaluronic and oleic acids (HAOA) 
was added to the gold nanoparticles. Natural polymers can work as reducing and 
capping agents, activating “green” reduction of gold and being less toxic for healthy 
tissues, which make them advantageous in the reduction and morphology of gold 
nanoparticles [42]. Furthermore, the use of polymeric coatings is also interesting as a 
way to control drug release and to increase the adsorption of ligands. Recently, Su et al. 
(2014) showed that HA scaffolds can increase the adsorption and sustained release of 
EGF, attached to the polymeric surface through self-assembly and electrostatic 
interactions [43]. In addition, HA is reported to confer structural stability to proteins [20]. 
Herein, we studied the effect of mounting EGF to HAOA-coated gold nanoparticles. In 
Fig. 5, it can be observed that EGF-conjugated HAOA-coated gold nanoparticles show 
the gold core (dark core) surrounded by HAOA polymer. On the upper left corner of Fig. 
5 is displayed a model of the EGF-conjugated HAOA-coated gold nanoparticles. Kinetic 
data displayed in Table 4 and Fig. 6 confirms that the polymers and the gold core 
promoted protein quenching and induced slower decay kinetics when compared with the 
data obtained with free EGF, protecting EGF from photochemistry. The same has been 
reported by Oliveira Silva et al. (2015) when studying the photochemistry of free 
lysozyme and comparing it to the photochemistry of lysozyme mounted onto HAOA-
coated gold nanoparticles [24]. It is likely that the structure of EGF, after conjugation to 
HAOA-coated nanoparticles, sustains excitation at 295 nm for longer time periods, prior 
to possible loss of structure and function. The presence of EGF conjugated to the HAOA-
coated gold nanoparticles was confirmed by fluorescence spectroscopy, after 
centrifugation and re-suspension with PBS, demonstrating a clear emission peak at 326 
nm for Trp residues (Fig. 7). The conjugation of EGF onto HAOA-coated gold 
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nanoparticles conferred enhanced photostability to EGF. This is observed in Fig. 8, 
where a smaller intensity reduction occurs in both fluorescence excitation spectra (41.0% 
versus 81.2%) and fluorescence emission spectra (25.7% versus 74.8%), after 295 nm 
continuous illumination. Furthermore, the observed blue shift in the fluorescence 
emission spectra of free EGF, after 295 nm continuous illumination, is no longer visible 
for EGF-conjugated HAOA-coated gold nanoparticles (Fig. 8). This is probably due to 
the fact that conjugation of EGF has prevented conformational changes that rendered 
the Trp moieties more apolar, responsible for the blue shift. SYPRO® Orange was used 
as an extrinsic probe for monitoring UV-light (295 nm) induced conformational changes 
in EGF (Fig. 9). Firstly, it was observed that SYPRO® Orange showed affinity towards 
hydrophobic moieties in HAOA-coated gold nanoparticles, leading to an increase of its 
fluorescence emission intensity signal compared to its fluorescence emission intensity in 
free EGF solution (Fig. 9). Secondly, the fluorescence emission spectra of EGF-
conjugated HAOA-coated nanoparticles suffered a red shift (from 584 nm to 638 nm) 
after 2 hours of continuous 295 nm illumination. On the other hand, the fluorescence 
emission spectra of free EGF suffered a blue shift (from 610 nm to 594 nm) after 2 hours 
of continuous 295 nm illumination. The observed red shift for SYPRO® Orange reveals 
that the probe is in a more polar environment after illumination.  
 
Finally, the antioxidant compounds of Plectranthus saccatus, present in the HAOA-
coated nanoparticles formulation, can also have an important role in protecting EGF from 
light induced reactions. Phenolic compounds are highly present in natural plant extracts 
and are described to show anti-oxidant effects on Trp oxidation and to be fluorescence 
quenchers [44–46]. It has been shown that the oxidation of the indole ring of Trp can be 
inhibited and, consequently, the formation of NFK and Kyn, by associating proteins with 
phenolic compounds from natural plant extracts [47]. This is positively correlated with 
our data. Conjugation of EGF to HAOA-coated gold nanoparticles reduced or even 
avoided the formation of photoproducts, such as NFK and Kyn (see Figs.10A and B).  
 
The presence of oxidative conditions induced by light can lead to the oxidation of the 
aromatic residues in proteins [1,2,6,33,48]. UVB excitation of aromatic residues in 
proteins leads to the disruption of SS bridges [1–4,6] and to the formation of 
photoproducts, such as N-formylkynurenine (NFK), kynurenine (Kyn) [26,49] and 
dityrosine (DT) [27]. Since 295 nm excites specifically Trp residues, it is very likely that 
the photoproducts formed are Trp derivatives such as NFK and Kyn and not Tyr 
derivatives like DT. Furthermore, the emission spectrum of EGF upon 295 nm leads to 
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a fluorescence emission spectrum that peaks around 330 nm, which makes it unlikely 
that Tyr residues will be excited by EGF emission. Two excitation wavelengths were 
used in order to detect the presence of photochemical products: 320 nm (Fig. 10A) and 
360 nm (Fig. 10B). Light at 320 nm excites both NFK (εNFK(321nm)=3750 M-1cm-1) [50–53] 
and Kyn (εKyn(321nm)= 1812 M-1cm-1) [54]. At 315 nm, DT has an extinction coefficient equal 
to 5200 M-1cm-1 but, as explained above, it is unlikely that it has been formed [55,56]. 
Light at 360 nm excites NFK (εNFK(360nm)=1607 M-1cm-1 [54] and Kyn (εKyn(365nm)=4530 M-
1cm-1 [57,58]) but does not excite DT. In Fig. 10A, the peak with maximum fluorescence 
emission intensity (320 nm excitation) for free EGF occurs at 418 nm and for EGF-
conjugated HAOA-coated occurs at 392 nm. In Fig. 10B, the peak with maximum 
fluorescence emission intensity (360 nm excitation) for free EGF occurs at 460 nm and 
for EGF-conjugated HAOA-coated nanoparticles it is seen at 461 nm. This peak cannot 
belong to DT, since DT is not excited at 360 nm. Therefore, it can be Kyn since the 
wavelength of maximum fluorescence emission of Kyn lies within 434-480 nm.  
 
Colocalization experiments carried out with confocal fluorescence microscopy (Fig. 11) 
confirmed that EGF (red colour) appears to be associated and colocalized with HAOA-
coated gold nanoparticles (green colour), which can be visualized as yellow coloured 
spots. Since EGF shows a pI around 4.55 and HAOA-coated gold nanoparticles have a 
superficial negative charge (-19 mV), attractive electrostatic interaction between the 
protein and the nanocarrier are not likely to occur at pH 7.4. In spite of this, a slight 
increase of the nanoparticles’ surface charge after EGF conjugation (-5 mV) is observed 
and, as already mentioned, the peptide conjugation onto the particles has also been 
confirmed by fluorescence spectroscopy. Moreover, literature described that EGF is 
likely to be associated to HA scaffolds through the polymer’s carboxylic groups and since 
HA is a hydrogel with high hygroscopic character, interactions between EGF and the 
polymer can occur by hydrophilic interactions [20,43,59]. Another possible mechanism 
for EGF conjugation onto HAOA-coated gold nanoparticles is by means of binding 
between an amino acid residue of the peptide and the HAOA coating or gold core. 
Histidine has been described as a very strong metal binding amino acid [60]. EGF has 
two histidine residues (His10 and His16). Lysine residues (Lys28 and Lys48) of EGF 
were also pointed out as a potential binding site for EGF conjugation with HA polymer 
[61], especially Lys48, which is located at the end of lateral chain of EGF.  
 
Far UV spectra for CD showed that EGF maintained its non-helical, random coil 
structure, before and after conjugation and after extraction from the HAOA-coated gold 
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nanoparticles, when incubated at 37 ºC in pH 5.5 phosphate buffer (Fig. 12). The native 
structure of EGF is described to be mainly composed of random coil elements (72%) and 
β-helical elements (25%) and only a trace of α-helical content [12,62]. The random coil 
secondary structure contributes to the presence of a negative peak at 200 – 210 nm [63]. 
Although a typical shoulder formation at 220 nm is described for EGF [63], as indicative 
of the presence of random non-helical forms and β-sheets, spectra with a flat curve 
around 215 – 225 nm is also expected for EGF, suggesting a low content on β forms 
[64]. It has been observed this flat curvature for all spectra of EGF samples above 215 
– 220 nm (Fig. 12). EGF-conjugated HAOA-coated gold nanoparticles showed a 
negative peak at 208 nm, as free EGF in its native form, in PBS pH 7.4. However, a 
spectral blue shift was detected for both EGF in supernatant, as for the unbound peptide, 
recovered after centrifugation of the EGF-conjugated HAOA-coated nanoparticles and 
EGF extracted after incubation of EGF-conjugated HAOA-coated gold nanoparticles in 
phosphate buffer pH 5.5, at 37 ºC, for 72 hours. Both EGF in the supernatant and 
extracted EGF’s peaks shifted to 206 nm. Furthermore, HAOA-coated gold 
nanoparticles, without EGF, showed an intense signal for the main negative peak at 200-
210 nm, with a minimum at 201 nm, which can be due to the fact that HAOA coating of 
gold nanoparticles, especially HA, also absorb in the far UV range [65].  
 
After characterizing the EGF-conjugated HAOA-coated gold nanoparticles in terms of 
pharmaceutical technology and protein stability, its potential biological application was 
evaluated. Firstly, the cell viability in normal-like human keratinocytes (HaCaT cell line) 
was tested in order to verify if our nanoparticles were safe when in contact with a healthy 
non-cancer tissue (see Fig.13). Statistical analysis was based on Student’s t-test for 
comparisons between cell viability values with non-conjugated HAOA-coated gold 
nanoparticles [66] and EGF-conjugated HAOA-coated nanoparticles (present work). No 
significant differences (p > 0.05) were found between the viability of HaCat cells treated 
with HAOA-coated gold nanoparticles and EGF-conjugated HAOA-coated gold 
nanoparticles at equal concentrations. Finally, when testing the biologic activity of EGF-
conjugated HAOA-coated nanoparticles, compared to free EGF, for EGFR binding, we 
have used a well-studied cell model for described previously for Human EGFR Live Cell 
Fluorescent Biosensor Assay [32]. Therefore, it was observed that both peptides, in 
those different conditions, were able to bind to the receptor and activate its internalization 
(visible green fluorescence as shown in Fig.14), making possible the downstream signal 
transduction. It has been observed in our study that the antibody anti-EGFR 
competitively inhibits the binding of free EGF to EGFR, but not for EGF-conjugated to 
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HAOA-coated gold nanoparticles. Therefore, nanoparticles can also enter the A549 cells 
by a putative different internalization mechanism than EGFR-modulated internalization. 
EGF-conjugated HAOA-coated gold nanoparticles may modulate the endocytic 
pathways for entering the cells. One example is the use of other cell receptors, such as 
CD44, for which hyaluronic acid is a specific ligand, which are also described to be also 
overexpressed in many solid tumor cells including breast, melanoma and lung cancer, 
like the A549 cell model used in this study [67,68]. Quattal et al. (2011) confirmed this 
possibility when they demonstrated by fluorescence microscopy that HA-coated 
liposomes, made of high-molecular weight HA, led to increased uptake of liposomes by 
A549 cells, with high and irreversible binding affinity [69]. As observed in Fig.14, EGF-
conjugated HAOA-coated gold nanoparticles accumulate around the peri-nuclear area, 
but do not penetrate into the cell nucleus, after 1.5 hours-incubation. Wang et al. (2013) 
showed that lipid-coated gold nanoparticles promoted the formation of acidic 
compartments, which appear to be lamellar bodies, in A549 cells [70]. These vesicles 
appear to internalize the nanoparticles, allowing them to enter the cell. Wang et al. (2013) 
also state that internalization occurs as a result of the negative charge of gold 
nanoparticles penetrating the lung surfactant, which primarily contains a mixture of 
phosphatidyl choline and phosphatidyl glycerol lipids [70]. Other polymeric coated gold 
nanoparticles, also highly negatively charged (-40 mV) were retained in the 
endolysosomal compartments, also predominant presence at the perinuclear region, 
after 1 and 2 hours-incubation with A549 cells [71]. This internalization was reported to 
occur very quickly, around 1 hour to 2 hours, probably due to EGF small size and high 
affinity to EGFR. Maybe, as a consequence, the clearance is also faster in lysosomes 
and in cells with high expression of EGFR [72].  Finally, another study using A549 lung 
cancer cells, sulfhydryl-activated EGF conjugation with lipidic nanoparticles were 
colocalized with the labeled EGF receptors and the internalization of EGF-conjugated 
nanoparticles was visible [37]. Therefore, the EGF-conjugated HAOA-coated gold 
nanoparticles developed in this work show a potential application for near infrared (NIR, 
650-800 nm) photothermal therapy, which may efficiently destroy cancer cells. NIR 
photothermal therapy reduces the damage of the healthy tissue compared to visible 
photothermal therapy [73]. 
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5. Conclusions 
 
The photochemistry of free EGF, EGF-conjugated HAOA-coated nanoparticles and non-
conjugated nanoparticles (both coated and uncoated) has been compared as a function 
of 295 nm excitation power and temperature. EGF attachment to HAOA-coated 
nanoparticles was confirmed by fluorescence spectroscopy, confocal microscopy and 
circular dichroism. HAOA-coated gold nanoparticles protected EGF from 295 nm 
induced photochemistry and did not induce EGF denaturation, reducing the formation of 
photoproducts such as NFK and Kyn. EGF-conjugated HAOA-coated nanoparticles did 
not markedly decrease HaCaT cell viability and were able to enter the EGFR-
overexpressing tumor cell line A549, by different internalization mechanisms. 
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Abstract 
 
In this work in vivo efficiency and safety of multifunctional hybrid nanoparticulate systems 
for cutaneous melanoma treatment were assessed for a targeted photothermal therapy. 
Hairless severely immunocompromised mice were selected for xenograft models of 
inoculated A375 human melanoma cells. Tumor-bearing mice were monitored twice a 
week for weight, body conditions and tumor growth. For photothermal therapy studies, a 
near-infrared laser at 811 nm was used in combination with hyaluronic and oleic acids-
coated gold nanoparticles conjugated with Epidermal Growth Factor. This treatment 
allowed a tumor reduction of around 80% in volume and led to the formation of several 
necrotic foci, observed after histological analysis. No significant skin erythema at the 
irradiation zone was verified, as well as for other excised organs. In conclusion, 
conducted preliminary in vivo assays show the potential of this local anti-tumor therapies, 
based on multiple and specific targeted moieties conjugated with nanosystems.  
 
 
Keywords: Human melanoma; Xenograft model; Photothermal therapy; Multifunctional 
nanoparticles; Targeted delivery; Epidermal Growth Factor. 
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1. Introduction 
 
Pre-clinical studies for predicting efficiency and toxicity of anti-cancer therapies still 
depend mostly on animal models [1,2]. Several cancer models have been developed for 
pre-clinical animal studies, but xenograft models are still widely preferred, as they allow 
the transplant of human cancer cells into mice [3]. Immunocompromised animals are 
selected to avoid the rejection of the human cells by the mice immune system. In general, 
human melanoma xenograft models show many advantages, such as the possibility of 
human cells to interact directly with the murine stroma environment (i.e., lymphatic and 
blood vessels) and the possibility of controlling the tumor growth and experimental 
points, through a standardized technique of the injected cells [4]. Moreover, these 
orthotopic tumor models also allow the evaluation of anti-tumor efficacy with 
reproducibility, cost and time-effectiveness and are applicable to many cell lines [2].  
 
Human melanoma is characterized to have a hypervascular tissue and metastasis 
formation is associated with blood vessel density [5,6]. In addition, human melanoma 
shows a natural tumorogenic potential, promoting the cancer proliferative and invasive 
properties [4]. Xenografts of melanoma metastatic cells, such as A375 cells are used 
both for local orthotopic tumor development through intra-dermal (i.d.) administration [7], 
and for metastases appearance (e.g., lungs and brain), when administered intravenously 
(i.v.) via tail vein [8]. Local administration (i.d.) can hinder this effect as compared to 
subcutaneous (s.c.) or i.v. injected cells by the tail vein [4,7]. Thus, A375 human 
melanoma cell line has been used successfully in many pre-clinical studies [9–12]. 
 
As a result of the evolution of cancer study, nanotechnology has been applied, with a 
significant outcome, in cancer treatment and diagnosis, by helping in molecular 
characterization and detection of cancerous or even precancerous tissues, with high 
accuracy and specificity [13]. Several and complex drug delivery systems that have been 
developed in research environment are now reaching the pharmaceutical pipelines and 
clinical trials [14]. Aiming a specific ligand-target receptor mechanism for internalization 
by cancer cells, conjugation of drug delivery systems with polymers (e.g., polyethylene 
glycol (PEG)) and targeting moieties (e.g., hormones, growth factors and antibodies), by 
chemical coupling reaction or electrostatic interactions, can improve their specific 
accumulation in the tumor site [15,16]. 
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In terms of targeted therapies for melanoma, there is an enormous increase in the 
number of new medicines that enter clinical trials and are already available for patients 
[17]. Furthermore, novel approaches aiming a targeted and more efficient melanoma 
treatment are being studied, with promising outcomes, by the use of nanoparticles, such 
as in gene and cell therapies, light-based therapies (i.e., photothermal and photodynamic 
therapies) and chemotherapy [18]. In photothermal therapy, gold nanoparticles show a 
great flexibility for obtaining multifunctional systems, as a result of their plasmonic 
tunable properties and surface functionalization [19,20]. Recently, near infrared (NIR) 
light-based therapies are being intensively studied to promote activation of metallic-
based nanoparticles [21]. NIR light is slightly absorbed by the chromophores present in 
our healthy tissue (also called as the “optical window” or “therapeutic window”) and 
allows a greater penetration depth (approximately 10-20 mm) [19,22]. Moreover, 
research studies have shown that gold nanoparticles have greater accumulation and 
tumor residence, when administered directly into the tumor (i.e., via intra-tumor injection), 
rather than by systemic routes (e.g., tail vein i.v. injection) [23]. The addition of targeting 
moieties and ligands, by physical adsorption of a coating polymer or by the use of linkers, 
are also helpful in accomplishing a localized and selective therapy [21,24]. Additionally, 
nanoparticles are extensively applied as carriers for anti-cancer drugs. These systems 
are generally used to reduce systemic adverse effects of conventional chemotherapy, 
improving the therapeutic efficacy of drug and its biodistribution specifically at the tumor 
site, as a result of a higher drug accumulation in targeted tissue [25]. The uptake of 
nanoparticles by tumor cells can also occur by passive uptake, via the enhanced 
permeability and retention (EPR) effect, due to leaky tumor vasculature, as well as by 
active uptake, where targeting receptor-mediated internalization takes place [18,25,26].  
 
Herein, we aim to study the efficiency and safety of multifunctional nanoparticulate 
systems, conjugated with multiple targeting moieties specific for melanoma cells, applied 
to local and targeted phototherapy. Previously, we have developed and characterized 
the nanosystems: firstly, Epidermal Growth Factor (EGF) conjugated gold nanoparticles, 
coated with a biopolymer (Hyaluronic acid, HA) and oleic acid (OA), were developed for 
NIR photothermal therapy [27]. Thus, aiming the separated study of both strategies as 
cutaneous melanoma therapies, orthotropic models made from A375 cells were 
selected, since this cell line is described to overexpress multiple receptors with medical 
relevance, on the cells’ surface, such as: 1) CD44 receptors, which natural ligand is the 
hyaluronic acid, also present in the HAOA coating material of both developed 
nanoparticles [28] and 3) EGFR, for which EGF is also the natural peptide ligand [29].  
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2. Materials and methods 
 
2.1 Materials 
Gold (III) chloride trihydrate (HAuCl4) (PubChem ID: 24895143; Product number: 
G4022), L-ascorbic acid (L-AA) (PubChem ID: 24891246; Product number: A7506), 
silver nitrate (AgNO3) (PubChem ID: 24852543; Product number: S0139), hyaluronic 
acid (HA) sodium salt from Streptococcus equi (MW 7,000-250,000 g.mol-1) (PubChem 
ID: 24878223; Product number: 53747), oleic acid (OA) (MW 282.46 g.mol-1) (PubChem 
ID: 24886786; Product number: 75090) were all supplied from Sigma-Aldrich (Steinheim, 
Germany). Recombinant Human Epidermal Growth Factor (EGF) (PubChem ID: 
62253638) was purchased from Life Technologies. The water used for buffer preparation 
was purified through a Millipore system. Fetal Bovine Serum (FBS) and 
penicillin/streptomycin were supplied by Sigma-Aldrich (Steinheim, Germany), as of cell 
culture grade. Dulbecco's Modified Eagle's medium (DMEM) was supplied by Biowest 
(Nuaillé, France).  
 
2.2 Cell culture  
To conduct the in vivo preliminary assays for evaluation of both targeted photothermal 
and chemotherapies, human melanoma A375 cell line (ATCC® CRL-1619™) was 
selected for the implementation of cancer xenografts in immunodeficient mice. The 
human melanoma A375 cell line is commonly used for human xenograft models and has 
overexpressed receptors for all the two targeting moieties that are conjugated with the 
nanosystems we assessed the in vivo efficiency profile: Epidermal Growth Factor (EGF)/ 
Epidermal Growth Factor Receptors (EGFR) [29], Hyaluronic acid (HA)/ CD44 receptor 
[28]. Firstly, A375 cells were cultured in an incubator at 37 ºC and 5% CO2 for one week 
in DMEM with 10% FBS and 1% penicillin/streptomycin, to obtain a confluence around 
80%, before the day of the injection [3,12]. At the day of the injection, cells were treated 
with versene and NaCO3 for alkalinization and harvested with trypsin and EDTA. Then, 
cells were centrifuged at 800 x g for 5 min (Eppendorf AG, Hamburg, Germany) and re-
suspended in a 50 mL- falcon tube with Phosphate Buffer Saline pH 7.4 (USP XXX) for 
injection in mice.  
 
2.3 Human melanoma xenograft  
Hairless 42 days-old male SHO-SCID mice (code: 474, Charles River, Barcelona), 
immunosuppressed for T and B cells were selected for the formation of melanoma 
xenografts models. The compatibility in implementing models of melanoma xenografts 
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with A375 cells has been described in literature [30,31]. This study was conducted in 
accordance to the internationally accepted principles for laboratory animal use and care 
as found in Directive 2010/63/EU and the project was approved by the Portuguese 
Veterinary General Division (DGAV). Animals were allowed to adapt to the laboratory for 
7 days before testing and then they were maintained with food and water ad libitum and 
kept at 22.0 ± 1.0ºC with controlled 12 h light/dark cycle at Faculty of Pharmacy, 
University of Coimbra. After this period, cells from section 2.2 were inoculated in the fold-
back of the neck, using a 1 mL syringe (needle size: 25 G x 5/8 in.) at a concentration of 
1x106 A375 cells/ mouse in 200 µL of PBS pH 7.4 as described in the literature [9]. 
Animals were monitored twice a week for weight control, body conditions (body condition 
score, BCS), behavior and signs of tumor progression. The size of the tumor and rate of 
growth were measured until they reached the desired size (around 1,000 mm3) for 
inclusion in the study. Tumor volume was calculated by the following equation (1):  
 
(1) length (width)2 /2 
 
where length is the largest diameter and width is the smallest diameter perpendicular to 
the length.  
 
Follow-up was carried out in total over 60-90 days. After this period of evaluation, it was 
concluded that there was a small change in total weight, over time, and physical and 
behavioral conditions of the animals were kept stable.  
 
2.3.1 Photothermal therapy 
2.3.1.1 Preparation of the EGF-conjugated HAOA-coated gold nanoparticles 
Firstly, EGF-conjugated gold nanoparticles, coated with hyaluronic and oleic acids 
(HAOA-coated gold nanoparticles) were prepared as previously described [27]. Gold 
nanoparticles were produced based on the addition of an aqueous extract of 
Plectranthus saccatus (10 mg/mL) as the main reducing and capping agent. Then, the 
gold nanoparticles were allowed to react with the coating material HAOA for 15 min at 
800 rpm, with a final concentration 0.5 mg/mL. Next, the EGF peptide (10 µg/mL) was 
added to the formulation and allowed to interact with the HAOA-coated gold 
nanoparticles for 30 min at 800 rpm. EGF-conjugated HAOA-coated gold nanoparticles 
were stored for 24h at 4ºC, protected from light, and afterwards centrifuged at 10,900 x 
g for 10 min (Hermle Labortechnik Gmbh, type Z36HK, Wehingen, Germany) to remove 
unbound peptide. Finally, EGF-conjugated HAOA-coated gold nanoparticles were frozen 
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and lyophilized for 24 h at -50.0 ± 2.0ºC, in FreeZone 2.5 L Benchtop Freeze Dry System 
(Labconco, Kansas City, Missouri, USA) and stored at -20 ºC until the day of the in vivo 
experiment.  
 
2.3.1.2 Irradiation laser procedure  
In this preliminary test, the following parameters were evaluated, such as variations in 
tumor growth rate and weight of the mice over time, safety of laser application at 811 nm 
(power: 2.5 W/cm2) and the effectiveness of treatment with nanoparticles and laser at 
811 nm, at different exposure times (5 min and 10 min). The size and volume of the 
tumors were determined before and 24 h after treatment application. After the 
appearance of tumors (size ~1,000 mm3), mice were randomly chosen to integrate the 
different treatment groups: 1) only laser exposure during 5 min (n = 4); 2) Intra-tumoral 
injection of EGF-conjugated HAOA-coated gold nanoparticles and exposure to the laser 
for 5 min (n = 4); 4) Intra-tumoral injection of EGF-conjugated HAOA-coated gold 
nanoparticles and laser exposure for 10 min (n = 4); 5) Control group (i.e., no treatment) 
(n = 3). In the case of treatment with laser and nanoparticles, EGF-conjugated HAOA-
coated gold nanoparticles were reconstituted in Milli-Q water at the time of 
administration. EGF-conjugated HAOA-coated gold nanoparticles were injected at the 
tumor site (i.t.) at a concentration per mouse of 20 mg/kg in 100 µL. After 4 h of the 
injection EGF-conjugated HAOA gold nanoparticles, the animals were anesthetized with 
a mixture of Ketamine + Chlorpromazine 10 mg/kg (intramuscular, i.m. injection), and 
subjected to laser irradiation of 811 nm (JDSU L4-2495-003 coupled to a source 
Laserpak ARO-485 -08-05) with a diameter of 2 mm and power at the target of 2.5 
W/cm2. The significance of differences was assessed using a Student’s t-test conducted 
for independent (unpaired) samples for weight and size measurements of the organs 
and tumors, for each group (p <0.01 vs. control, as the significance level). 
 
2.3.1.3. Evaluation of phototherapy-induced in vivo safety and efficacy 
Before and after laser exposure, mice were also evaluated for possible formation of 
erythema, at the irradiation zone, by colorimetry (a *, AU) (Minolta Chroma meter CR-
300, Konica Minolta Sensing Americas, Inc. NJ, USA) (Figure 1). The significance of 
differences was assessed using a Student’s t-test that was conducted for independent 
(unpaired) samples for weight and size measurements of the organs and tumors, for 
each group (p <0.01 vs. control (before irradiation), as the significance level). 
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2.3.1.4. Evaluation of phototherapy-induced in vivo efficacy 
For histological evaluation, 24 h after each treatment previously described, animals were 
sacrificed according animal welfare principles. Tumor and organs (i.e., lungs, heart, liver, 
spleen and kidneys) were excised, weighed and measured. Then, organs were fixed in 
10% formalin, paraffin embedded, and cut into five-micrometer sections for hematoxylin-
eosin staining. Slices were examined under an Olympus BX51 microscope (Olympus 
Corporation, Tokio, Japan) and images were taken using an Olympus U-TV1X-2 color 
camera and the extent of tumor necrosis was analyzed with Olympus analySIS software 
(Olympus Corporation, Tokio, Japan).  
 
 
 
Figure 1. Illustrated scheme of melanoma xenograft models assessed for in vivo anti-
cancer efficiency with photothermal therapy. 
 
 
3. Results 
 
3.1 Induction and follow-up of human xenograft models of melanoma in 
hairless SCID mice 
The variation of tumors growth in SHO-SCID mice was high, ranging from 2 weeks to 2 
months. In spite of this fact, SCID mice showed stable body conditions with a BCS > 3. 
All mice were monitored for 60-90 days, showing an average weight of 28.5 ± 1.5 g 
(mean ± SD, n = 15). The weight was kept within these values throughout the study. In 
addition, all rodents showed a normal water and food intake, normal respiratory activity, 
posture (independently from the size of the tumor) and mobility. After necropsies, control 
and treated groups showed similar histological morphology and size of internal organs 
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(i.e., except the tumor), namely lungs (right and left), spleen, heart, kidneys (right and 
left) and liver. The average weight and measures (for heart and spleen), for each group 
included in the photothermal therapy, are represented in Table 1, showing that there was 
no important variation in size of the organs. No micro or macrometastases for melanoma 
were found in the lungs and there were no size variations of these organs between 
control and test groups. As for the tumors, the average weight and volume was 0.46 ± 
0.03 g and 773.3 ± 51.5 mm3 (mean ± SEM; n = 15). Statistical analysis as Student’s t-
test (*p<0.01) showed that there were no significant differences for the treatment groups 
compared to the control, in terms of weight and size of the organs.  
 
Table 1. Average weight of excised organs after treatment or as control groups, for 
photothermal therapy. Size measures were taken for the heart and spleen of the mice. 
Results are presented as mean ± SEM. Legend: (R) - Right; (L) – Left.   
 
Group Organ Weight (g) Size (mm3) 
Control  
(n = 3) 
Lungs 
R 0.163 ± 0.011 - 
L 0.060 ± 0.004 - 
Heart 0.183 ± 0.012 180.0 ± 12.0 
Kidneys 
R 0.260 ± 0.017 - 
L 0.247 ± 0.016 - 
Liver 1.723 ± 0.115 - 
Spleen 0.063 ± 0.004 141.5 ± 9.4 
Laser (5 min) 
(n = 4) 
Lungs 
R 0.141 ± 0.009 - 
L 0.055 ± 0.004 - 
Heart 0.174 ± 0.012 165.0 ± 11.0 
Kidneys 
R 0.248 ± 0.017 - 
L 0.248 ± 0.017 - 
Liver 1.477 ± 0.098 - 
Spleen 0.045 ± 0.003 81.0 ± 5.4 
Laser (5 min) + 
EGF-HAOA GNP 
(n = 4) 
Lungs 
R 0.118 ± 0.008 - 
L 0.055 ± 0.004 - 
Heart 0.151 ± 0.010 191.5 ± 12.8 
Kidneys 
R 0.242 ± 0.016 - 
L 0.233 ± 0.016 - 
Liver 1.856 ± 0.124 - 
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Spleen 0.048 ± 0.003 65.6 ± 4.4 
Laser (10 min) + 
EGF-HAOA GNP 
(n = 4) 
Lungs 
R 0.429 ± 0.029 - 
L 0.046 ± 0.003 - 
Heart 0.143 ± 0.010 146.1 ± 9.7 
Kidneys 
R 0.236 ± 0.016 - 
L 0.229 ± 0.015 - 
Liver 1.543 ± 0.103 - 
Spleen 0.060 ± 0.004 102.7 ± 6.8 
 
 
3.2 Photothermal therapy 
Mice with melanoma treated with photothermal therapy showed that laser at 811 nm 
applied with EGF-conjugated HAOA-coated nanoparticles promoted tumor local necrosis 
(Figure 2). Mice treated with EGF-conjugated HAOA-coated nanoparticles and 5 min-
exposure 811 nm laser beam showed a reduction to 81.1 ± 20.3% (mean ± SEM, n = 4). 
However, when we increased the laser exposure to 10 min, this value decreased to 32.3 
± 8.1% (mean ± SEM, n = 4). In addition, we have evaluated the degree of erythema (a 
*, AU) by colorimetry, before and after laser irradiation (mean ± SEM, n = 4 for each 
group). Results showed that there was a small change on the skin redness after laser 
irradiation alone for 5 min (Δa*= 0.44 ± 0.34 AU) and also for laser irradiation for 5 min 
after injection of the nanoparticles (Δa*= 1.44 ± 0.01 AU) and for 10 min laser irradiation 
after injection of nanoparticles (Δa*= 1.00 ± 0.25 AU). Statistical analysis as Student’s t-
test (*p <0.01) showed that there were no significant differences between the skin 
colorimetry, before and after irradiation, of each treatment group.   
 
In terms of histological analysis, it was observed the presence of several necrotic foci in 
tumor samples exposed to the laser at 811 nm for 5 min, combined with EGF-conjugated 
HAOA-coated gold nanoparticles, as mostly as coagulative necrosis (Figure 2). 
Regarding the laser irradiation alone (without local injection of nanoparticles), few 
morphological changes (< 30% extended necrosis) were also observed in the tumor 
tissue of the mice. As for the control groups, no histological or morphological changes 
were observed (Figure 2).  
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Figure 2. Histological images (400X microscopic approach) of the tumor tissue from the 
control group (i.e., without treatment), from the group treated with 811 nm-laser 
irradiation for 5 min and from the groups treated with i.t. administration of EGF-
conjugated HAOA-coated gold nanoparticles and 811 nm-laser irradiation for 5 and 10 
min. All tissues were marked with Hematoxylin-Eosin staining (H & E staining). 
 
 
Then, we compared the histology of the different organ’s tissues (i.e., heart, kidney, liver, 
spleen, lung and normal skin without tumor) in mice after exposure to laser irradiation at 
811 nm for 5 min combined with EGF-conjugated HAOA-coated gold nanoparticles and 
the control group since a high tumor volume reduction was observed. Similarly, the 
histology of the mice’s organs (i.e., heart, kidney, liver, spleen and lung), exposed to the 
laser and nanoparticles confirm that there were no morphological changes and were 
comparable to the control (Figure 3), suggesting a very localized inoculation of tumor 
cells and treatment. Dermis tissue from normal skin sample was, as expected, a stratified 
epithelium, fibrous with sweat glands, present in the fatty tissue (hypodermis).  
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Figure 3. Histological images (400X microscopic approach) of the tumor tissue from the 
control group (i.e., without treatment) and from the group treated with 811 nm-laser 
irradiation for 5 min and i.t. administration of EGF-conjugated HAOA-coated gold 
nanoparticles. Each image is representative of the organs removed for analysis after 
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necropsy (i.e., heart, kidney, liver, spleen, lung and skin). All tissues were marked with 
Hematoxylin-Eosin staining (H & E staining). 
 
 
4. Discussion 
 
Preliminary results obtained in the present in vivo studies indicated that both therapeutic 
strategies induce cancer cells death and may avoid melanoma progression to more 
aggressive stages. Hairless SCID mice used in this study have been bread by crossing 
an outbred SCID with an immunocompetent outbred hairless mouse (SKH1), resulting in 
hairless immunocompromised SCID mice with higher tumor engraftment efficiency than 
athymic nude mice. Although the animals have defects in T and B cell development, 
which results in absent murine T and B lymphocytes, they have high natural killer (NK) 
cell levels [31]. Xenograft models are normally successfully recreated but some variation 
can occur. In this study, we wanted to develop a localized cutaneous melanoma and not 
to recreate a model for metastatic and angiogenic melanoma. Therefore, SCID animals 
were selected, since they tend to reduce formation of metastases and delay cell growth, 
as demonstrated for transformed A375 cell line with lung tropism due to the presence of 
NK cells [32]. As a consequence, an increased variation in tumor growth was verified. 
Another research group have studied the variability of implantation of human melanoma 
cells from patients into NOD/SCID mice, showing that there was a high variability and 
that it could take more than 32 weeks for tumors to develop [33]. It was determined that 
less than 105 cells per injection would fail greatly to form tumors in mice. Between 105 
and 107 cell per injection, a palpable tumor appeared after 8 weeks. When using Matrigel 
(25%), melanoma cells become highly tumorigenic and, therefore, tumors were formed 
faster (around 7 weeks). Matrigel can stimulate a faster tumor growth, but also influence 
the cancer cells metastatic behavior and expression, since the addition of angiogenic 
factors, present in Matrigel composition, modify the conditions of the tumor extracellular 
matrix [34, 35]. On the other hand, it is known that melanoma shows natural tumorigenic 
potential, which is related with the malignant behavior of cancer cells [4,36].  
 
EGF-conjugated HAOA-coated gold nanoparticles were tested in association with a 811 
nm-laser for 5 min at 2.5 W/cm2, as the photothermal therapy for cutaneous melanoma. 
By photothermal therapy, tumors exposed to NIR laser and nanoparticles showed a 
characteristic coagulative necrosis, resulting from denaturation of the tissue structural 
proteins [37–39]. Therefore, histological images appear pale in staining since there is a 
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loss of cytoplasmatic and nuclear matter. In presence of tumor and without local injection 
of the nanoparticles, some necrosis foci were observed (< 30%) after laser irradiation (5 
and 10 min). In spite of this, after laser irradiation also, the mice’s skin integrity was 
maintained, as the dermis kept its stratified epithelium and fibrous with sweat glands, 
present in the fatty tissue (hypodermis), which can be associated to the low temperature 
reached at the site of the irradiation (< 40ºC). The latter was also observed in other 
studies [40,41]. NIR laser irradiation has been reported to not cause any type of 
morphological tissue damage or cause less than 10% of necrosis after irradiation [39]. 
Different laser parameters were selected in those studies: in the first study, where the 
laser caused no damage, irradiation was conducted at a wavelength of 785 nm, for 10 
min with a power of 9.5 W/cm2; in the second study, laser irradiation occurred at a 
wavelength of 808 nm, for 1 min at a power of 0.5 W/cm2 [39]. NIR lasers are considered 
as safe for skin irradiation and to penetrate deeper (up to 10 mm) than UV-visible laser 
[19,22]. However, it has been reported the presence of thermal side effects and 
coagulative necrosis in skin tissues, where NIR-laser was applied alone, mainly for the 
first biological window (650–900 nm) region [42–44]. This can be avoided if the epidermal 
skin area is efficiently cooled (< 20 ºC) before laser irradiation [42,43]. Therefore, it is 
critical to always verify the safety of the laser irradiation, at specific experimental 
conditions, in every study. As an alternative, the actual use of low fluency lasers, such 
as nanosecond and femtosecond lasers, allow a localized energy transfer, which induces 
a temporary increase of cell permeability without affecting cell viability [45]. 
 
Regarding the treatment with EGF-conjugated HAOA-coated gold nanoparticles, the 
nanoparticles were administered 4 h before laser irradiation, via single i.t. injection. 
Further, after 24 h -post laser irradiation for 5 min, several necrotic foci were detected. 
In this case, a high tumor volume reduction was observed after laser irradiation. Several 
factors may contribute to this reduction. Firstly, it is known that gold nanoparticles reach 
their maximum absorption after the laser irradiation, promoting local hyperthermia of the 
tissues (temperature in the range 41–47°C) and, consequently, irreversible cell damage 
caused by the disruption of cell’s membrane permeability and protein denaturation 
[21,46]. Hyperthermia is known to induce apoptotic cell death in many tissues and has 
been shown to increase local control and overall survival in combination with 
radiotherapy and chemotherapy in randomised clinical trials. Normal tumor vasculature 
dilates to aid heat dissipation, tumor vasculature constricts, providing some tumor 
selectivity [46]. Secondly, the combination of polymeric coatings and bio-conjugation 
avoid interactions with the immune cells and capture of the nanoparticles by the 
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mononuclear phagocyte system (i.e., spleen, liver and lung) [47]. In our case, EGF-
conjugated HAOA-coated nanoparticles showed a size around 100-200 nm, a negative 
surface change (- 5 mV) and a spherical morphology. Tumor tissue has leaky vasculature 
and, thus, it may be possible an accumulation of the nanoparticles in this tissue occurred 
by both EPR effect and active binding of the EGF ligand to overexpressed EGFR [48,49]. 
As in another study, clusters of iron oxide magnetic nanoparticles for NIR-laser PTT were 
developed by Shen et al. (2015) for testing on A549 human lung adenocarcinoma 
epithelial cell line [50]. The clusters were prepared by a modified solvothermal reaction, 
in autoclave, and administered i.t. in mice. After 2 h of cell-nanoparticle interaction, 
tumors were irradiated with a 808 nm continuous-wave NIR laser at 5 W/cm2. Clustered 
nanoparticles were more efficient than individual nanoparticles inducing tumor local 
hyperthermia, reaching a temperature around 50 ºC and killing 72.8% of cancerous cells; 
in spite of this, the clusters were slowly cleared from the tumor after therapy, being 
detected several days after the treatment in the mice’s organism [50]. In our study, we 
have accomplished a high tumor reduction (> 80%), demonstrating an effective 
hyperthermia and tumor destruction, at lower temperature values.  
 
Finally, orthotopic xenografts models are widely used in pre-clinical studies, as they 
easily allow the establishment of primary tumor or human transplanted cells to in vivo 
conditions. However, these models do not reproduce exactly the tumor 
microenvironment and cannot always represent the vast heterogeneity and complexity 
of cancer tissues [4,51]. Immunodeficient environment, as a consequence for xenograft 
human cells acceptance, can also compromise the tumor architecture and 
microenvironment [4,51]. Cutaneous melanoma is a very heterogeneous cancer 
associated with many signaling pathways and mutations that divide this cancer in several 
subtypes. Thus, this cancer is one of the most challenging and clinically complex in terms 
of anti-cancer drug efficacy studies.  
 
 
5. Conclusions 
 
Hybrid nanosystems were developed, comprising multiple targeting moieties for an 
active uptake by melanoma cells by photothermal therapy. Palpable tumors were 
assessed for volume growth after 15 days. Internal organs, such as, heart, lungs, liver, 
spleen and kidneys did not show any structural change, suggesting a very localized 
tumor cell inoculation. We also observed that the laser did not affect or slightly affected 
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the skin integrity. In presence of the tumor, photothermal therapy showed that the light-
absorbing nanoparticles improved coagulative necrosis and strongly reduced the volume 
of the tumors. The study of molecular mechanisms behind this anti-cancer effects on 
human melanoma is still ongoing. Further, we will concentrate on the association of 
laser-activated drug delivery systems, comprising an anti-cancer drug, as a promising 
approach for an effective melanoma therapy. 
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CONCLUSIONS 
 
The experimental work included in this thesis aimed the design and characterization of 
novel formulations based on hybrid nanoparticles for two different strategies in 
cutaneous melanoma targeted therapy. Briefly, hybrid gold nanoparticles were designed 
for a photothermal therapy approach (physical approach) and hybrid polymeric-lipidic 
nanoparticles were developed for chemotherapy (chemical approach). The results 
obtained allowed us to conclude the following points:  
 
1. Polymeric-lipidic nanoparticles, made of poly-ε-caprolactone and stearic acid, 
showed high encapsulation efficiency, improved drug stability and sustained drug 
release of the topical glucocorticosteroid, betamethasone-21-acetate. In addition, 
coating with the permeation enhancer, oleic acid, increased drug permeation in 
vitro and in vivo animal models, without causing skin irritation or other side 
effects.  
 
2. Gold nanoparticles were successfully produced by reduction with an aqueous 
extract of Plectranthus saccatus Benth., rich in rosmarinic, caffeic and 
chlorogenic acids, allowed us to obtain clusters of 100 nm-sized nanoparticles, 
with a spherical morphology and a surface plasmon band at near infrared region 
(830 nm). These nanoparticles were successfully coated with hyaluronic and 
oleic acids (HAOA), maintaining their physico-chemical characteristics, a safe in 
vitro toxicity profile and responding to thermal activation (up to 50ºC).  
 
3. Conjugation of HAOA-coated gold nanoparticles with lysozyme (herein used as 
a model protein) showed that these hybrid nanoparticles were able to positively 
incorporate this model protein, by electrostatic interactions. In addition, HAOA-
coated gold nanoparticles enhanced the protection of this protein against UV 
photodegradation, reducing the fluorescence decay of the aromatic residues, 
mainly tryptophan, and the formation of photo-oxidative products.  
 
4. Conjugation of HAOA-coated gold nanoparticles with Epidermal Growth Factor 
(EGF) showed that these hybrid nanoparticles were also able to successfully 
incorporate such a key relevant medical peptide, by electrostatic interactions. 
HAOA-coated gold nanoparticles also increased EGF UV photostability and 
reduced the formation of photo-degradation products. In addition, EGF-
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conjugated HAOA-coated gold nanoparticles were actively internalized by tumor 
cells through EGFR-mediated endocytosis and showed safe in vitro cytotoxic 
profile over normal-like cells.  
 
5. Coating of hybrid polymeric-lipid nanoparticles, made from poly-ε-caprolactone 
and stearic acid, with hyaluronic and oleic acids (HAOA) was also successful and 
increased the sustained release of a novel anti-tumor compound, Parvifloron D, 
extracted from Plectranthus eckloni, with remarkable cytotoxic action but low 
selectivity. Parvifloron D showed a fast onset and high potency in vitro anti-tumor 
action. HAOA-coated hybrid nanoparticles showed a size of 300 nm and a 
spherical shell-core structure, confirmed by several physico-chemical 
techniques. In addition, α-Melanocyte Stimulating Hormone (α-MSH) was 
positively conjugated onto HAOA-coated hybrid nanoparticles, by electrostatic 
interactions. In vitro cytotoxicity and internalization studies showed that those 
nanoparticles were uptaken by tumor cells (B16V5 and A375), according to 
different mechanisms.  
 
6. In vivo efficiency studies showed that both therapeutic approaches promoted 
necrosis of human cutaneous melanoma cells in xenograft models of 
immunodeficient mices. Near infrared-based photothermal therapy in association 
with EGF-conjugated HAOA-coated gold nanoparticles reduced tumor volume in 
80% and caused several coagulative necrotic foci on tumor tissue, but no 
significant damage of the surrounding tissue or other side effects. Meanwhile, 
local chemotherapy with Parvifloron D and α-MSH-conjugated HAOA-coated 
polymeric-lipidic nanoparticles promoted an extensive necrosis of the tumors (up 
to 90%).  
 
7. Finally, we can conclude that it is possible to modify different nanosystems, 
starting from different core structures, and modulating the surface through a 
successful and broad functionalization with multiple and distinct targeting 
moieties. Thus, different therapeutic strategies can be applied in heterogeneous 
cancers, such as cutaneous melanoma, destroying the tumor by diverse 
approaches. Physico-chemical characterization and both in vitro and in vivo 
biologic models are, therefore, crucial to obtain a robust, reproducible and 
efficient hybrid nanosystem. 
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8. As future prospect, we aim to conjugate synergistically both therapies studied in 
this thesis. Therefore, we will continue to study the functionalization of hybrid 
nanoparticles with different anti-tumor targeting moieties, comprising a light-
absorbing core, for photothermal therapy, and a polymeric structure, capable of 
sustaining the release of novel anti-tumor drugs, for a local chemotherapy.  
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